STOCK TITAN

[10-Q] Waystar Holding Corp. Quarterly Earnings Report

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
10-Q
Rhea-AI Filing Summary

Kiniksa Pharmaceuticals International, plc (KNSA) has filed a Form 144 to notify the SEC of an intended insider sale.

  • Shares to be sold: 64,508 common shares
  • Aggregate market value: $1,928,595.68
  • Approximate sale date: 07/30/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Shares outstanding: 74,107,668

The shares were acquired the same day (07/30/2025) through the exercise of employee stock options under a registered plan and will be sold for cash. No other sales by this insider were reported in the past three months.

The proposed disposition equals roughly 0.09% of total shares outstanding, indicating a modest, routine-sized transaction rather than a large liquidation. The filer attests to having no undisclosed material adverse information and confirms compliance with Rule 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentato un Modulo 144 per notificare alla SEC una vendita interna prevista.

  • Azioni da vendere: 64.508 azioni ordinarie
  • Valore di mercato complessivo: 1.928.595,68 $
  • Data approssimativa di vendita: 30/07/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Azioni in circolazione: 74.107.668

Le azioni sono state acquisite lo stesso giorno (30/07/2025) tramite l'esercizio di opzioni azionarie per dipendenti nell'ambito di un piano registrato e saranno vendute per contanti. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di questo insider.

La disposizione proposta corrisponde a circa il 0,09% delle azioni totali in circolazione, indicando una transazione modesta e di routine piuttosto che una liquidazione consistente. Il dichiarante attesta di non possedere informazioni materiali negative non divulgate e conferma la conformità alla Regola 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentado un Formulario 144 para notificar a la SEC sobre una venta interna prevista.

  • Acciones a vender: 64,508 acciones ordinarias
  • Valor de mercado agregado: $1,928,595.68
  • Fecha aproximada de venta: 30/07/2025
  • Corredor: Morgan Stanley Smith Barney LLC, Nueva York
  • Acciones en circulación: 74,107,668

Las acciones fueron adquiridas el mismo día (30/07/2025) mediante el ejercicio de opciones sobre acciones para empleados bajo un plan registrado y se venderán por efectivo. No se reportaron otras ventas por parte de este insider en los últimos tres meses.

La disposición propuesta equivale aproximadamente al 0.09% del total de acciones en circulación, lo que indica una transacción modesta y rutinaria en lugar de una liquidación grande. El declarante asegura no tener información material adversa no divulgada y confirma el cumplimiento con la Regla 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA)는 내부자 매각 예정 사실을 SEC에 알리기 위해 Form 144를 제출했습니다.

  • 판매 예정 주식 수: 보통주 64,508주
  • 총 시장 가치: $1,928,595.68
  • 예상 판매일: 2025년 7월 30일
  • 중개인: Morgan Stanley Smith Barney LLC, 뉴욕
  • 발행 주식 총수: 74,107,668주

해당 주식은 동일한 날(2025년 7월 30일) 직원 스톡옵션 행사로 등록된 계획 하에 취득되었으며 현금으로 판매될 예정입니다. 지난 3개월간 이 내부자의 다른 매각 보고는 없었습니다.

이번 매각 예정 물량은 전체 발행 주식의 약 0.09%에 해당하며, 대규모 청산보다는 소규모 일상 거래임을 나타냅니다. 제출자는 공개되지 않은 중대한 부정적 정보가 없음을 확인하며 Rule 10b5-1 준수를 선언합니다.

Kiniksa Pharmaceuticals International, plc (KNSA) a déposé un Formulaire 144 pour informer la SEC d'une vente interne prévue.

  • Actions à vendre : 64 508 actions ordinaires
  • Valeur marchande totale : 1 928 595,68 $
  • Date approximative de vente : 30/07/2025
  • Intermédiaire : Morgan Stanley Smith Barney LLC, New York
  • Actions en circulation : 74 107 668

Les actions ont été acquises le même jour (30/07/2025) par l'exercice d'options d'achat d'actions pour employés dans le cadre d'un plan enregistré et seront vendues contre espèces. Aucune autre vente par cet initié n'a été signalée au cours des trois derniers mois.

La cession proposée représente environ 0,09 % du total des actions en circulation, indiquant une transaction modeste et habituelle plutôt qu'une liquidation importante. Le déclarant certifie ne détenir aucune information défavorable importante non divulguée et confirme le respect de la règle 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) hat ein Formular 144 eingereicht, um die SEC über einen geplanten Insider-Verkauf zu informieren.

  • Zu verkaufende Aktien: 64.508 Stammaktien
  • Gesamtmarktwert: 1.928.595,68 $
  • Ungefähres Verkaufsdatum: 30.07.2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Ausstehende Aktien: 74.107.668

Die Aktien wurden am selben Tag (30.07.2025) durch Ausübung von Mitarbeiteraktienoptionen im Rahmen eines registrierten Plans erworben und werden gegen Barzahlung verkauft. In den letzten drei Monaten wurden keine weiteren Verkäufe dieses Insiders gemeldet.

Die vorgeschlagene Veräußerung entspricht etwa 0,09 % der ausstehenden Gesamtaktien und deutet auf eine bescheidene, routinemäßige Transaktion statt einer größeren Liquidation hin. Der Einreicher bestätigt, keine nicht offengelegten wesentlichen negativen Informationen zu besitzen und die Einhaltung der Regel 10b5-1.

Positive
  • None.
Negative
  • Insider plans to sell 64,508 shares (~0.09% of 74.1 M outstanding) valued at $1.93 M

Insights

TL;DR: Small insider sale (0.09% OS) worth $1.9 M; signals routine diversification, limited fundamental impact.

The Form 144 shows an insider intends to sell 64,508 newly-exercised option shares, worth about $1.93 million, through Morgan Stanley on 07/30/2025. Given 74.1 million shares outstanding, the sale is immaterial to float and does not suggest broad insider pessimism. Lack of prior 3-month sales and same-day option exercise point to liquidity/tax planning rather than a directional bet. Investors typically view such filings as neutral unless accompanied by larger cluster selling. I rate the filing neutral for valuation and trading outlook.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentato un Modulo 144 per notificare alla SEC una vendita interna prevista.

  • Azioni da vendere: 64.508 azioni ordinarie
  • Valore di mercato complessivo: 1.928.595,68 $
  • Data approssimativa di vendita: 30/07/2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Azioni in circolazione: 74.107.668

Le azioni sono state acquisite lo stesso giorno (30/07/2025) tramite l'esercizio di opzioni azionarie per dipendenti nell'ambito di un piano registrato e saranno vendute per contanti. Negli ultimi tre mesi non sono state segnalate altre vendite da parte di questo insider.

La disposizione proposta corrisponde a circa il 0,09% delle azioni totali in circolazione, indicando una transazione modesta e di routine piuttosto che una liquidazione consistente. Il dichiarante attesta di non possedere informazioni materiali negative non divulgate e conferma la conformità alla Regola 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) ha presentado un Formulario 144 para notificar a la SEC sobre una venta interna prevista.

  • Acciones a vender: 64,508 acciones ordinarias
  • Valor de mercado agregado: $1,928,595.68
  • Fecha aproximada de venta: 30/07/2025
  • Corredor: Morgan Stanley Smith Barney LLC, Nueva York
  • Acciones en circulación: 74,107,668

Las acciones fueron adquiridas el mismo día (30/07/2025) mediante el ejercicio de opciones sobre acciones para empleados bajo un plan registrado y se venderán por efectivo. No se reportaron otras ventas por parte de este insider en los últimos tres meses.

La disposición propuesta equivale aproximadamente al 0.09% del total de acciones en circulación, lo que indica una transacción modesta y rutinaria en lugar de una liquidación grande. El declarante asegura no tener información material adversa no divulgada y confirma el cumplimiento con la Regla 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA)는 내부자 매각 예정 사실을 SEC에 알리기 위해 Form 144를 제출했습니다.

  • 판매 예정 주식 수: 보통주 64,508주
  • 총 시장 가치: $1,928,595.68
  • 예상 판매일: 2025년 7월 30일
  • 중개인: Morgan Stanley Smith Barney LLC, 뉴욕
  • 발행 주식 총수: 74,107,668주

해당 주식은 동일한 날(2025년 7월 30일) 직원 스톡옵션 행사로 등록된 계획 하에 취득되었으며 현금으로 판매될 예정입니다. 지난 3개월간 이 내부자의 다른 매각 보고는 없었습니다.

이번 매각 예정 물량은 전체 발행 주식의 약 0.09%에 해당하며, 대규모 청산보다는 소규모 일상 거래임을 나타냅니다. 제출자는 공개되지 않은 중대한 부정적 정보가 없음을 확인하며 Rule 10b5-1 준수를 선언합니다.

Kiniksa Pharmaceuticals International, plc (KNSA) a déposé un Formulaire 144 pour informer la SEC d'une vente interne prévue.

  • Actions à vendre : 64 508 actions ordinaires
  • Valeur marchande totale : 1 928 595,68 $
  • Date approximative de vente : 30/07/2025
  • Intermédiaire : Morgan Stanley Smith Barney LLC, New York
  • Actions en circulation : 74 107 668

Les actions ont été acquises le même jour (30/07/2025) par l'exercice d'options d'achat d'actions pour employés dans le cadre d'un plan enregistré et seront vendues contre espèces. Aucune autre vente par cet initié n'a été signalée au cours des trois derniers mois.

La cession proposée représente environ 0,09 % du total des actions en circulation, indiquant une transaction modeste et habituelle plutôt qu'une liquidation importante. Le déclarant certifie ne détenir aucune information défavorable importante non divulguée et confirme le respect de la règle 10b5-1.

Kiniksa Pharmaceuticals International, plc (KNSA) hat ein Formular 144 eingereicht, um die SEC über einen geplanten Insider-Verkauf zu informieren.

  • Zu verkaufende Aktien: 64.508 Stammaktien
  • Gesamtmarktwert: 1.928.595,68 $
  • Ungefähres Verkaufsdatum: 30.07.2025
  • Broker: Morgan Stanley Smith Barney LLC, New York
  • Ausstehende Aktien: 74.107.668

Die Aktien wurden am selben Tag (30.07.2025) durch Ausübung von Mitarbeiteraktienoptionen im Rahmen eines registrierten Plans erworben und werden gegen Barzahlung verkauft. In den letzten drei Monaten wurden keine weiteren Verkäufe dieses Insiders gemeldet.

Die vorgeschlagene Veräußerung entspricht etwa 0,09 % der ausstehenden Gesamtaktien und deutet auf eine bescheidene, routinemäßige Transaktion statt einer größeren Liquidation hin. Der Einreicher bestätigt, keine nicht offengelegten wesentlichen negativen Informationen zu besitzen und die Einhaltung der Regel 10b5-1.

000199035412-312025falseQ2P2Y258xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureway:segmentway:installmentway:clientway:vendor00019903542025-01-012025-06-3000019903542025-07-2100019903542025-06-3000019903542024-12-310001990354us-gaap:NonrelatedPartyMember2025-06-300001990354us-gaap:NonrelatedPartyMember2024-12-310001990354us-gaap:RelatedPartyMember2025-06-300001990354us-gaap:RelatedPartyMember2024-12-3100019903542025-04-012025-06-3000019903542024-04-012024-06-3000019903542024-01-012024-06-300001990354us-gaap:NonrelatedPartyMember2025-04-012025-06-300001990354us-gaap:NonrelatedPartyMember2024-04-012024-06-300001990354us-gaap:NonrelatedPartyMember2025-01-012025-06-300001990354us-gaap:NonrelatedPartyMember2024-01-012024-06-300001990354us-gaap:RelatedPartyMember2025-04-012025-06-300001990354us-gaap:RelatedPartyMember2024-04-012024-06-300001990354us-gaap:RelatedPartyMember2025-01-012025-06-300001990354us-gaap:RelatedPartyMember2024-01-012024-06-300001990354us-gaap:CommonStockMember2025-03-310001990354us-gaap:AdditionalPaidInCapitalMember2025-03-310001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001990354us-gaap:RetainedEarningsMember2025-03-3100019903542025-03-310001990354us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001990354us-gaap:CommonStockMember2025-04-012025-06-300001990354us-gaap:RetainedEarningsMember2025-04-012025-06-300001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001990354us-gaap:CommonStockMember2025-06-300001990354us-gaap:AdditionalPaidInCapitalMember2025-06-300001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001990354us-gaap:RetainedEarningsMember2025-06-300001990354us-gaap:CommonStockMember2024-03-310001990354us-gaap:AdditionalPaidInCapitalMember2024-03-310001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001990354us-gaap:RetainedEarningsMember2024-03-3100019903542024-03-310001990354us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001990354us-gaap:CommonStockMember2024-04-012024-06-300001990354us-gaap:RetainedEarningsMember2024-04-012024-06-300001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001990354us-gaap:CommonStockMember2024-06-300001990354us-gaap:AdditionalPaidInCapitalMember2024-06-300001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001990354us-gaap:RetainedEarningsMember2024-06-3000019903542024-06-300001990354us-gaap:CommonStockMember2024-12-310001990354us-gaap:AdditionalPaidInCapitalMember2024-12-310001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001990354us-gaap:RetainedEarningsMember2024-12-310001990354us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-300001990354us-gaap:CommonStockMember2025-01-012025-06-300001990354us-gaap:RetainedEarningsMember2025-01-012025-06-300001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300001990354us-gaap:CommonStockMember2023-12-310001990354us-gaap:AdditionalPaidInCapitalMember2023-12-310001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001990354us-gaap:RetainedEarningsMember2023-12-3100019903542023-12-310001990354us-gaap:AdditionalPaidInCapitalMember2024-01-012024-06-300001990354us-gaap:CommonStockMember2024-01-012024-06-300001990354us-gaap:RetainedEarningsMember2024-01-012024-06-300001990354us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-06-300001990354way:SubscriptionAndVolumeBasedRevenueMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-06-300001990354srt:MinimumMember2025-01-012025-06-300001990354srt:MaximumMember2025-01-012025-06-300001990354way:ImplementationFeesAndHardwareSalesMemberus-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2025-01-012025-06-300001990354way:IncrementalCostsOfObtainingContractMember2025-06-300001990354way:IncrementalCostsOfObtainingContractMember2024-12-310001990354way:IncrementalCostsOfObtainingContractMember2025-04-012025-06-300001990354way:IncrementalCostsOfObtainingContractMember2024-04-012024-06-300001990354way:IncrementalCostsOfObtainingContractMember2025-01-012025-06-300001990354way:IncrementalCostsOfObtainingContractMember2024-01-012024-06-300001990354way:CostsToFulfillContractMember2025-06-300001990354way:CostsToFulfillContractMember2024-12-310001990354way:CostsToFulfillContractMember2025-04-012025-06-300001990354way:CostsToFulfillContractMember2024-04-012024-06-300001990354way:CostsToFulfillContractMember2025-01-012025-06-300001990354way:CostsToFulfillContractMember2024-01-012024-06-300001990354us-gaap:SubscriptionAndCirculationMember2025-04-012025-06-300001990354us-gaap:SubscriptionAndCirculationMember2024-04-012024-06-300001990354us-gaap:SubscriptionAndCirculationMember2025-01-012025-06-300001990354us-gaap:SubscriptionAndCirculationMember2024-01-012024-06-300001990354way:VolumeBasedRevenueMember2025-04-012025-06-300001990354way:VolumeBasedRevenueMember2024-04-012024-06-300001990354way:VolumeBasedRevenueMember2025-01-012025-06-300001990354way:VolumeBasedRevenueMember2024-01-012024-06-300001990354way:ImplementationServicesAndOtherRevenueMember2025-04-012025-06-300001990354way:ImplementationServicesAndOtherRevenueMember2024-04-012024-06-300001990354way:ImplementationServicesAndOtherRevenueMember2025-01-012025-06-300001990354way:ImplementationServicesAndOtherRevenueMember2024-01-012024-06-3000019903542025-07-012025-06-3000019903542026-01-012025-06-300001990354way:ReportableSegmentMember2025-04-012025-06-300001990354way:ReportableSegmentMember2024-04-012024-06-300001990354way:ReportableSegmentMember2025-01-012025-06-300001990354way:ReportableSegmentMember2024-01-012024-06-300001990354us-gaap:CommercialPaperMember2025-06-300001990354us-gaap:CorporateNoteSecuritiesMember2025-06-300001990354us-gaap:USTreasuryBillSecuritiesMember2025-06-300001990354us-gaap:USGovernmentAgenciesDebtSecuritiesMember2025-06-300001990354us-gaap:CommercialPaperMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300001990354us-gaap:CommercialPaperMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-06-300001990354us-gaap:CommercialPaperMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-06-300001990354us-gaap:CommercialPaperMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-06-300001990354us-gaap:CorporateNoteSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300001990354us-gaap:CorporateNoteSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-06-300001990354us-gaap:CorporateNoteSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-06-300001990354us-gaap:CorporateNoteSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-06-300001990354us-gaap:USTreasuryBillSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300001990354us-gaap:USTreasuryBillSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-06-300001990354us-gaap:USTreasuryBillSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-06-300001990354us-gaap:USTreasuryBillSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-06-300001990354us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300001990354us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-06-300001990354us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-06-300001990354us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-06-300001990354us-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300001990354us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-06-300001990354us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-06-300001990354us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310001990354us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2024-12-310001990354us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2024-12-310001990354us-gaap:InterestRateSwapMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel3Member2024-12-310001990354way:FirstLienTermLoanFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LineOfCreditMember2025-06-300001990354way:FirstLienTermLoanFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LineOfCreditMember2024-12-310001990354way:FirstLienTermLoanFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LineOfCreditMember2025-06-300001990354way:FirstLienTermLoanFacilityMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:LineOfCreditMember2024-12-310001990354us-gaap:ComputerEquipmentMember2025-06-300001990354us-gaap:ComputerEquipmentMember2024-12-310001990354us-gaap:SoftwareDevelopmentMember2025-06-300001990354us-gaap:SoftwareDevelopmentMember2024-12-310001990354us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2025-06-300001990354us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001990354us-gaap:FurnitureAndFixturesMember2025-06-300001990354us-gaap:FurnitureAndFixturesMember2024-12-310001990354us-gaap:OfficeEquipmentMember2025-06-300001990354us-gaap:OfficeEquipmentMember2024-12-310001990354us-gaap:LeaseholdImprovementsMember2025-06-300001990354us-gaap:LeaseholdImprovementsMember2024-12-310001990354way:InternalUseSoftwareInProgressMember2025-06-300001990354way:InternalUseSoftwareInProgressMember2024-12-310001990354us-gaap:CustomerRelationshipsMember2025-06-300001990354us-gaap:DevelopedTechnologyRightsMember2025-06-300001990354us-gaap:TrademarksAndTradeNamesMember2025-06-300001990354us-gaap:CustomerRelationshipsMember2024-12-310001990354us-gaap:DevelopedTechnologyRightsMember2024-12-310001990354us-gaap:TrademarksAndTradeNamesMember2024-12-310001990354way:ReceivablesFacilityMemberus-gaap:LineOfCreditMember2025-06-300001990354way:ReceivablesFacilityMemberus-gaap:LineOfCreditMember2024-12-310001990354way:ReceivablesFacilityMemberus-gaap:LineOfCreditMember2025-01-012025-06-300001990354way:ReceivablesFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrMemberus-gaap:LineOfCreditMember2025-01-012025-06-300001990354way:ReceivablesFacilityMemberus-gaap:BaseRateMemberus-gaap:LineOfCreditMember2025-01-012025-06-300001990354way:FirstLienTermLoanFacilityMemberus-gaap:LineOfCreditMember2025-06-300001990354way:FirstLienTermLoanFacilityMemberus-gaap:LineOfCreditMember2024-12-310001990354us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-06-300001990354us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-12-310001990354us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2025-01-012025-06-300001990354way:FirstLienTermLoanFacilityMemberus-gaap:LineOfCreditMember2025-01-012025-06-300001990354way:InterestRateSwapOneMember2025-06-300001990354way:InterestRateSwapOneMember2024-12-310001990354way:InterestRateSwapTwoMember2025-06-300001990354way:InterestRateSwapTwoMember2024-12-310001990354way:InterestRateSwapThreeMember2025-06-300001990354way:InterestRateSwapThreeMember2024-12-310001990354way:InterestRateSwapFourMember2025-06-300001990354way:InterestRateSwapFourMember2024-12-310001990354us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-04-012025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-01-012025-06-300001990354us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-06-300001990354way:FirstLienTermLoanFacilityMembersrt:AffiliatedEntityMemberus-gaap:LineOfCreditMember2025-06-300001990354way:FirstLienTermLoanFacilityMembersrt:AffiliatedEntityMemberus-gaap:LineOfCreditMember2024-12-310001990354srt:AffiliatedEntityMember2025-04-012025-06-300001990354srt:AffiliatedEntityMember2024-04-012024-06-300001990354srt:AffiliatedEntityMember2025-01-012025-06-300001990354srt:AffiliatedEntityMember2024-01-012024-06-3000019903542024-06-100001990354way:StockIncentivePlan2019Member2019-10-220001990354way:StockIncentivePlan2019Member2019-10-222019-10-220001990354way:StockIncentivePlan2019Memberus-gaap:EmployeeStockOptionMember2019-10-222019-10-220001990354way:EquityIncentivePlan2024Member2024-06-060001990354way:EquityIncentivePlan2024Member2024-06-062024-06-060001990354way:EquityIncentivePlan2024Memberus-gaap:EmployeeStockOptionMember2024-06-062024-06-060001990354us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMemberway:EquityIncentivePlan2024Member2024-06-062024-06-060001990354us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMemberway:EquityIncentivePlan2024Member2024-06-062024-06-060001990354us-gaap:PerformanceSharesMembersrt:MinimumMemberway:EquityIncentivePlan2024Member2024-06-062024-06-060001990354us-gaap:PerformanceSharesMembersrt:MaximumMemberway:EquityIncentivePlan2024Member2024-06-062024-06-060001990354way:EquityIncentivePlan2024Memberus-gaap:PerformanceSharesMember2025-01-012025-06-300001990354way:EquityIncentivePlan2024Member2025-06-300001990354way:EmployeeStockPurchasePlan2024Member2024-06-060001990354way:EmployeeStockPurchasePlan2024Member2024-06-062024-06-060001990354srt:MaximumMemberway:EmployeeStockPurchasePlan2024Member2024-06-060001990354way:EmployeeStockPurchasePlan2024Memberus-gaap:EmployeeStockMember2024-06-062024-06-060001990354us-gaap:EmployeeStockMember2025-01-012025-06-300001990354us-gaap:EmployeeStockMember2025-04-012025-06-300001990354us-gaap:EmployeeStockMember2024-01-012024-06-300001990354us-gaap:EmployeeStockMember2024-04-012024-06-300001990354us-gaap:EmployeeStockOptionMember2025-01-012025-06-3000019903542024-01-012024-12-3100019903542023-01-012023-12-310001990354us-gaap:EmployeeStockOptionMember2025-04-012025-06-300001990354us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001990354us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001990354srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-04-012024-06-300001990354srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-04-012024-06-300001990354srt:MinimumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001990354srt:MaximumMemberus-gaap:EmployeeStockOptionMember2024-01-012024-06-300001990354us-gaap:RestrictedStockUnitsRSUMember2024-12-310001990354us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-06-300001990354us-gaap:RestrictedStockUnitsRSUMember2025-06-300001990354us-gaap:RestrictedStockUnitsRSUMember2023-12-310001990354us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001990354us-gaap:RestrictedStockUnitsRSUMember2024-06-300001990354us-gaap:PerformanceSharesMember2024-01-012024-12-310001990354us-gaap:PerformanceSharesMember2025-04-012025-06-300001990354us-gaap:PerformanceSharesMember2025-01-012025-06-300001990354us-gaap:PerformanceSharesMember2024-12-310001990354us-gaap:PerformanceSharesMember2025-06-300001990354us-gaap:CostOfSalesMember2025-04-012025-06-300001990354us-gaap:CostOfSalesMember2024-04-012024-06-300001990354us-gaap:CostOfSalesMember2025-01-012025-06-300001990354us-gaap:CostOfSalesMember2024-01-012024-06-300001990354us-gaap:GeneralAndAdministrativeExpenseMember2025-04-012025-06-300001990354us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001990354us-gaap:GeneralAndAdministrativeExpenseMember2025-01-012025-06-300001990354us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001990354us-gaap:SellingAndMarketingExpenseMember2025-04-012025-06-300001990354us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-300001990354us-gaap:SellingAndMarketingExpenseMember2025-01-012025-06-300001990354us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-300001990354us-gaap:ResearchAndDevelopmentExpenseMember2025-04-012025-06-300001990354us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001990354us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-06-300001990354us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001990354way:VotingSharesMember2025-04-012025-06-300001990354way:VotingSharesMember2024-04-012024-06-300001990354way:VotingSharesMember2025-01-012025-06-300001990354way:VotingSharesMember2024-01-012024-06-300001990354us-gaap:EmployeeStockOptionMemberway:VotingSharesMember2025-04-012025-06-300001990354us-gaap:EmployeeStockOptionMemberway:VotingSharesMember2024-04-012024-06-300001990354us-gaap:EmployeeStockOptionMemberway:VotingSharesMember2025-01-012025-06-300001990354us-gaap:EmployeeStockOptionMemberway:VotingSharesMember2024-01-012024-06-300001990354us-gaap:RestrictedStockUnitsRSUMemberway:VotingSharesMember2025-04-012025-06-300001990354us-gaap:RestrictedStockUnitsRSUMemberway:VotingSharesMember2024-04-012024-06-300001990354us-gaap:RestrictedStockUnitsRSUMemberway:VotingSharesMember2025-01-012025-06-300001990354us-gaap:RestrictedStockUnitsRSUMemberway:VotingSharesMember2024-01-012024-06-300001990354us-gaap:EmployeeStockMemberway:VotingSharesMember2025-04-012025-06-300001990354us-gaap:EmployeeStockMemberway:VotingSharesMember2024-04-012024-06-300001990354us-gaap:EmployeeStockMemberway:VotingSharesMember2025-01-012025-06-300001990354us-gaap:EmployeeStockMemberway:VotingSharesMember2024-01-012024-06-300001990354srt:ScenarioForecastMemberway:IodineSoftwareHoldingsInc.Member2025-07-232025-12-310001990354way:EricLeeRicSinclairIIIMember2025-04-012025-06-300001990354way:MatthewHawkinsMember2025-04-012025-06-300001990354way:MatthewHawkinsMember2025-06-30
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x    QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2025
OR
    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File Number 001-42125
Waystar Holding Corp.
(Exact name of registrant as specified in its charter)
Delaware
84-2886542
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
1550 Digital Drive, #300
Lehi, Utah 84043
84043
(Address of principal executive offices)(Zip Code)
(844) 492-9782
Registrant’s telephone number, including area code
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per share
WAY
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerAccelerated filer
Non-accelerated filer
xSmaller reporting company
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No x
The registrant had outstanding 174,238,972 shares of common stock as of July 21, 2025.


Table of Contents
Glossary
The following definitions apply to these terms as used in this Quarterly Report on Form 10-Q:
“AI” means artificial intelligence;
“Bain” means those certain investment funds of Bain Capital, LP and its affiliates;
“CPPIB” means Canada Pension Plan Investment Board;
“Credit Facilities” means, collectively, the First Lien Credit Facility, the Revolving Credit Facility, and the Receivables Facility;
“Derby Topco” means Derby TopCo Partnership LP, our direct parent entity prior to the Equity Distribution, in which the Institutional Investors, other equity holders, and certain members of management previously held equity interests;
“EQT” means those certain investment funds of EQT AB and its affiliates;
“Equity Distribution” means the distribution of shares of common stock of the Company held by Derby TopCo to the limited partners of Derby TopCo in accordance with the limited partnership agreement of Derby Topco, which distribution occurred in connection with our initial public offering. Following the Equity Distribution, EQT, CPPIB, Bain, and other equity holders, including members of management, directly hold shares of common stock of the Company;
“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended;
“First Lien Credit Facility” means the term loan credit facility under the first lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;
“GAAP” means U.S. generally accepted accounting principles;
“Institutional Investors” means EQT, CPPIB, and Bain, and their respective affiliates;
“JOBS Act” means the U.S. Jumpstart Our Business Startups Act of 2012, as amended;
“Net Revenue Retention Rate” means the total amount invoiced to clients in a given twelve-month period divided by the total amount invoiced to those same clients from the prior twelve-month period. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Performance Metrics and Non-GAAP Financial Measures—Net Revenue Retention Rate”;
“2024 Form 10-K” means the 2024 Form 10-K filed with the SEC by Waystar Holding Corp. on February 18, 2025;
“Receivables Facility” means the receivables facility under the receivables financing agreement, dated as of August 13, 2021, by and among Waystar RC LLC, PNC Bank, National Association, as administrative agent, Waystar Technologies, Inc., as initial servicer, and PNC Capital Markets LLC, as structuring agent, as amended from time to time;
“Revolving Credit Facility” means the revolving credit facility under the first lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;
“SEC” means the U.S. Securities and Exchange Commission;
“Second Lien Credit Facility” means the term loan credit facility under the second lien credit agreement, dated as of October 22, 2019, by and among Waystar Technologies, Inc. and the lenders party thereto, as amended from time to time;
“Securities Act” means the U.S. Securities Act of 1933, as amended;
“SOFR” means the Secured Overnight Financing Rate; and
“Waystar,” the “Company,” “we,” “us,” and “our” mean the business of Waystar Holding Corp. and its subsidiaries.


Table of Contents
Certain numerical figures have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them.
Cautionary Statement Regarding Forward-Looking Statements
This report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts. These forward-looking statements are included throughout this report and relate to matters such as our industry, business strategy, goals, and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity, and capital resources and other financial and operating information. We have used the words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative version of these words or similar terms and phrases to identify forward-looking statements in this report.
The forward-looking statements contained in this report are based on management’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Our expectations, beliefs, and projections are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:
our operation in a highly competitive industry;
our ability to retain our existing clients and attract new clients;
our ability to successfully execute on our business strategies in order to grow;
our ability to accurately assess the risks related to acquisitions and successfully integrate acquired businesses, including the previously announced acquisition of Iodine Software Holdings, Inc. (“Iodine”);
our ability to establish and maintain strategic relationships;
the growth and success of our clients and overall healthcare transaction volumes;
consolidation in the healthcare industry;
our selling cycle of variable length to secure new client agreements;
our implementation cycle that is dependent on our clients’ timing and resources;
our dependence on our senior management team and certain key employees, and our ability to attract and retain highly skilled employees;
the accuracy of the estimates and assumptions we use to determine the size of our total addressable market;
our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes, or evolving industry standards;
the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures;
the performance and reliability of internet, mobile, and other infrastructure;
the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions;


Table of Contents
our reliance on certain third-party vendors and providers;
any errors or malfunctions in our products and solutions;
failure by our clients to obtain proper permissions or provide us with accurate and appropriate information;
the potential for embezzlement, identity theft, or other similar illegal behavior by our employees or vendors, and a failure of our employees or vendors to observe quality standards or adhere to environmental, social, and governance standards;
our compliance with the applicable rules of the National Automated Clearing House Association and the applicable requirements of card networks;
increases in card network fees and other changes to fee arrangements;
the effect of payer and provider conduct which we cannot control;
privacy concerns and security breaches or incidents relating to our platform;
the complex and evolving laws and regulations regarding privacy, data protection, and cybersecurity;
our ability to adequately protect and enforce our intellectual property rights;
our ability to use or license data and integrate third-party technologies;
our use of “open source” software;
legal proceedings initiated by third parties alleging that we are infringing or otherwise violating their intellectual property rights;
claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties;
the heavily regulated industry in which we conduct business;
the uncertain and evolving healthcare regulatory and political framework;
health care laws and data privacy and security laws and regulations governing our Processing of personal information;
reduced revenues in response to changes to the healthcare regulatory landscape;
legal, regulatory, and other proceedings that could result in adverse outcomes;
consumer protection laws and regulations;
contractual obligations requiring compliance with certain provisions of Bank Secrecy Act/anti-money laundering laws and regulations;
existing laws that regulate our ability to engage in certain marketing activities;
our full compliance with website accessibility standards;
any changes in our tax rates, the adoption of new tax legislation, or exposure to additional tax liabilities;
limitations on our ability to use our net operating losses to offset future taxable income;
losses due to asset impairment charges;


Table of Contents
restrictive covenants in the agreements governing our Credit Facilities;
interest rate fluctuations;
unavailability of additional capital on acceptable terms or at all;
the impact of general macroeconomic conditions;
our history of net losses and our ability to achieve or maintain profitability;
the interests of the Institutional Investors may be different than the interests of other holders of our securities;
our status as an “emerging growth company” and whether the reduced disclosure requirements applicable to “emerging growth companies” will make our common stock less attractive to investors; and
the other factors described elsewhere in this report, including under the headings “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Quantitative and Qualitative Disclosures About Market Risk” and Part II, Item 1A, “Risk Factors” or as described under the heading “Risk factors” in our 2024 Form 10-K, or as described in the other documents and reports we file with the SEC.
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this report. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.
Any forward-looking statements made by us in this report speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. You should not place undue reliance on our forward-looking statements. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by any applicable securities laws.
Investors and others should note that we routinely announce financial and other material information using our Investor Relations website (investors.waystar.com), SEC filings, press releases, public conference calls and webcasts. We use these channels of distribution to communicate with our investors and members of the public about our company, our services and other items of interest. Information contained on our website is not part of this report or our other filings with the SEC.


Table of Contents
Table of Contents
Page
Part I - Financial Information
Item 1. Financial Statements
1
Unaudited Condensed Consolidated Balance Sheets
1
Unaudited Condensed Consolidated Statements of Operations
2
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss)
3
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity
4
Unaudited Condensed Consolidated Statements of Cash Flows
6
Notes to Unaudited Condensed Consolidated Financial Statements
7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
26
Item 3. Quantitative and Qualitative Disclosures About Market Risk
36
Item 4. Controls and Procedures
37
Part II - Other Information
Item 1. Legal Proceedings
38
Item 1A. Risk Factors
38
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchase of Securities
38
Item 3. Defaults Upon Senior Securities
38
Item 4. Mine Safety Disclosures
38
Item 5. Other Information
38
Item 6. Exhibits
38
Signatures
41
i

Table of Contents
Part I - Financial Information
Item 1. Financial Statements
Waystar Holding Corp.
Unaudited Condensed Consolidated Balance Sheets (in Thousands, Except for Share and Per Share Data)
June 30, 2025December 31, 2024
Assets
Current assets
Cash and cash equivalents$290,300 $182,133 
Restricted cash21,169 22,449 
Investment securities50,493  
Accounts receivable, net of allowance of $6,104 at June 30, 2025 and $5,885 at December 31, 2024
143,498 145,235 
Income tax receivable 2,838 
Prepaid expenses15,942 14,414 
Other current assets3,077 3,972 
Total current assets524,479 371,041 
Property, plant and equipment, net47,387 46,731 
Operating lease right-of-use assets, net8,960 10,820 
Intangible assets, net982,818 1,039,049 
Goodwill3,019,999 3,019,999 
Deferred costs88,083 82,815 
Other long-term assets6,196 6,549 
Total assets$4,677,922 $4,577,004 
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$46,737 $47,365 
Accrued compensation22,413 31,589 
Aggregated funds payable20,888 22,059 
Other accrued expenses35,314 15,930 
Deferred revenue9,540 10,527 
Current portion of long-term debt11,102 11,311 
Related party current portion of long-term debt566 357 
Current portion of operating lease liabilities5,330 5,591 
Current portion of finance lease liabilities950 904 
Total current liabilities152,840 145,633 
Long-term liabilities
Deferred tax liability107,557 100,523 
Long-term debt, net, less current portion1,160,234 1,185,411 
Related party long-term debt, net, less current portion55,628 35,211 
Operating lease liabilities, net of current portion10,575 13,133 
Finance lease liabilities, net of current portion10,801 11,290 
Deferred revenue - long-term5,545 5,739 
Other long-term liabilities1,602 278 
Total liabilities1,504,782 1,497,218 
Commitments and contingencies (Note 20)
Stockholders’ equity
Preferred stock $0.01 par value - 100,000,000 and 100,000,000 shares authorized as of June 30, 2025 and December 31, 2024, respectively; zero shares issued or outstanding as of June 30, 2025 and December 31, 2024, respectively
  
Common stock $0.01 par value - 2,500,000,000 and 2,500,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 174,146,070 and 172,108,240 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively
1,741 1,722 
Additional paid-in capital3,331,277 3,298,083 
Accumulated other comprehensive income (loss)(431)881 
Accumulated deficit(159,447)(220,900)
Total stockholders’ equity3,173,140 3,079,786 
Total liabilities and stockholders’ equity$4,677,922 $4,577,004 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1

Table of Contents
Waystar Holding Corp.
Unaudited Condensed Consolidated Statements of Operations (in Thousands, Except for Share and Per Share Data)
Three months ended June 30,Six months ended June 30,
2025202420252024
Revenue$270,654 $234,543 $527,089 $459,335 
Operating expenses
Cost of revenue (exclusive of depreciation and amortization expenses)87,044 80,451 170,389 155,643 
Sales and marketing43,524 45,715 83,647 79,495 
General and administrative29,192 39,955 52,492 66,090 
Research and development12,622 15,901 23,700 26,221 
Depreciation and amortization33,426 44,276 66,806 88,450 
Total operating expenses205,808 226,298 397,034 415,899 
Income from operations64,846 8,245 130,055 43,436 
Other expense
Interest expense(17,325)(49,195)(35,582)(105,007)
Related party interest expense(930)(1,346)(1,573)(2,718)
Income/(loss) before income taxes46,591 (42,296)92,900 (64,289)
Income tax expense/(benefit)14,407 (14,611)31,447 (20,672)
Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
Net income/(loss) per share:
Basic$0.19 $(0.21)$0.36 $(0.34)
Diluted$0.18 $(0.21)$0.34 $(0.34)
Weighted-average shares outstanding:
Basic173,358,382133,527,766172,467,988127,601,532
Diluted181,599,133133,527,766181,076,149127,601,532
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2

Table of Contents
Waystar Holding Corp.
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) (in Thousands)
Three months ended June 30,Six months ended June 30,
2025202420252024
Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
Other comprehensive income (loss), before tax:
Interest rate swaps(971)(5,944)(1,689)(6,184)
Available-for-sale securities(20) (32) 
Income tax effect:
Interest rate swaps239 1,443 401 1,508 
Available-for-sale securities5  8  
Other comprehensive income/(loss), net of tax(747)(4,501)(1,312)(4,676)
Comprehensive income/(loss), net of tax$31,437 $(32,186)$60,141 $(48,293)

(1)Amounts reclassified out of accumulated other comprehensive income/(loss) into net interest expense included $1,257 and $8,695 for the three months ended June 30, 2025 and 2024, respectively, and included $1,889 and $17,297 for the six months ended June 30, 2025 and 2024, respectively.
(2)The income tax effects of amounts reclassified out of accumulated other comprehensive income/(loss) were ($309) and ($2,111) for the three months ended June 30, 2025 and 2024, respectively, and $(465) and $(4,200) for the six months ended June 30, 2025 and 2024, respectively.
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

Table of Contents
Waystar Holding Corp.
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (in Thousands, Except Share Data)
Three months ended June 30, 2025
Common StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
SharesAmount
Balances, March 31, 2025172,963,709$1,730 $3,315,497 $316 $(191,631)$3,125,912 
Share-based compensation— 11,432 — — 11,432 
Settlement of common stock options, net of stock option exercises721,9997 4,352 — — 4,359 
Vesting of restricted stock units460,3624 (4)— —  
Net income— — — 32,184 32,184 
Other comprehensive income (loss)— — (747)— (747)
Balances at June 30, 2025174,146,070$1,741 $3,331,277 $(431)$(159,447)$3,173,140 
Three months ended June 30, 2024
Common StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
SharesAmount
Balances, March 31, 2024121,659,634 $1,217 $2,236,350 $15,627 $(217,707)$2,035,487 
Stock-based compensation— — 37,390 — — 37,390 
Settlement of common stock options, net of stock option exercises— — (11)— — (11)
Capital distributions— — (99)— — (99)
Issuance of common stock in initial public offering, net of issuance costs45,000,000 450 905,067 — — 905,517 
Net loss— — — — (27,685)(27,685)
Other comprehensive income (loss)— — — (4,501)— (4,501)
Balances at June 30, 2024166,659,634 $1,667 $3,178,697 $11,126 $(245,392)$2,946,098 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

Table of Contents
Waystar Holding Corp.
Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Equity (in Thousands, Except Share Data)
Six months ended June 30, 2025
Common StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
SharesAmount
Balances at December 31, 2024172,108,240$1,722 $3,298,083 $881 $(220,900)$3,079,786 
Share-based compensation— 18,168 — — 18,168 
Settlement of common stock options, net of stock option exercises1,577,46815 15,030 — — 15,045 
Vesting of restricted stock units460,3624 (4)— —  
Net income— — — 61,453 61,453 
Other comprehensive income (loss)— — (1,312)— (1,312)
Balances at June 30, 2025174,146,070$1,741 $3,331,277 $(431)$(159,447)$3,173,140 
Six months ended June 30, 2024
Common StockAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
SharesAmount
Balances at December 31, 2023121,679,902$1,217 $2,234,688 $15,802 $(201,775)$2,049,932 
Stock-based compensation— 39,918 — — 39,918 
Settlement of common stock options, net of stock option exercises2,4201 (34)— — (33)
Repurchase of shares(22,688)(1)(843)— — (844)
Capital distributions— (99)— — (99)
Issuance of common stock in initial public offering, net of issuance costs45,000,000450 905,067 — — 905,517 
Net loss— — — (43,617)(43,617)
Other comprehensive income (loss)— — (4,676)— (4,676)
Balances at June 30, 2024166,659,634$1,667 $3,178,697 $11,126 $(245,392)$2,946,098 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

Table of Contents
Waystar Holding Corp.
Unaudited Condensed Consolidated Statements of Cash Flows (in Thousands)
Six months ended June 30,
20252024
Cash flows from operating activities
Net income/(loss)$61,453 $(43,617)
Adjustments to reconcile net income/(loss) to net cash provided by operating activities
Depreciation and amortization66,806 88,450 
Stock-based compensation18,274 39,497 
Provision for bad debt expense1,872 1,055 
Loss on extinguishment of debt 19,016 
Deferred income taxes7,437 (42,377)
Amortization of debt discount and issuance costs1,346 2,646 
Other (99)
Changes in:
Accounts receivable(135)(22,932)
Income tax refundable2,838 (4,371)
Prepaid expenses and other current assets(968)(2,319)
Deferred costs(5,140)(10,945)
Other long-term assets58 (442)
Accounts payable and accrued expenses9,308 4,392 
Deferred revenue(1,181)(910)
Operating lease right-of-use assets and lease liabilities(959)(864)
Net cash provided by operating activities161,009 26,180 
Cash flows from investing activities
Purchase of property and equipment and capitalization of internally developed software costs(11,193)(12,428)
Purchase of investment securities(50,525) 
Net cash used in investing activities(61,718)(12,428)
Cash flows from financing activities
Change in aggregated funds liability(1,171)2,327 
Proceeds from equity offering, net of underwriting discounts 914,288 
Payments of third-party IPO issuance costs (1,982)
Repurchase of shares (844)
Proceeds from exercise of common stock options15,045 (33)
Proceeds from issuances of debt, net of creditor fees 535,209 
Payments on debt(5,834)(1,425,874)
Third-party fees paid in connection with issuance of new debt (1,410)
Finance lease liabilities paid(444)(403)
Net cash provided by financing activities7,596 21,278 
Increase in cash and cash equivalents during the period106,887 35,030 
Cash and cash equivalents and restricted cash–beginning of period204,582 45,428 
Cash and cash equivalents and restricted cash–end of period$311,469 $80,458 
Supplemental disclosures of cash flow information
Interest paid$39,745 $82,264 
Cash taxes paid (refunds received), net8,346 26,141 
Non-cash investing and financing activities
Fixed asset purchases in accounts payable195 363 
Unpaid third-party IPO issuance costs 1,354 
Reconciliation of Balance Sheet Cash Accounts to Cash Flow Statement
Balance sheet
Cash and cash equivalents290,300 68,375 
Restricted cash21,169 12,083 
Total311,469 80,458 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements

1. Business
Waystar Holding Corp. (“Waystar”, “we”, “us” or “our”) is a provider of mission-critical cloud technology to healthcare organizations. Our enterprise-grade platform transforms the complex and disparate processes comprising healthcare payments received by healthcare providers from payers and patients, from pre-service engagement through post-service remittance and reconciliation. Our platform enhances data integrity, eliminates manual tasks, and improves claim and billing accuracy, which results in better transparency, reduced labor costs, and faster, more accurate reimbursement and cash flow. The market for our solutions extends throughout the United States and includes Puerto Rico and other U.S. Territories.
Risks and Uncertainties— We are subject to risks common to companies in similar industries, including, but not limited to, our operation in a highly competitive industry, our ability to retain our existing clients and attract new clients, our ability to establish and maintain strategic relationships, the growth and success of our clients and overall healthcare transaction volumes, consolidation in the healthcare industry, our selling cycle of variable length to secure new client agreements, our implementation cycle that is dependent on our clients’ timing and resources, our ability to develop and market new solutions, or enhance our existing solutions, to respond to technological changes or evolving industry standards, the interoperability, connectivity, and integration of our solutions with our clients’ and their vendors’ networks and infrastructures, the performance and reliability of internet, mobile, and other infrastructure, the consequences if we cannot obtain, process, use, disclose, or distribute the highly regulated data we require to provide our solutions, impact of government regulations on our market, and our reliance on certain third-party vendors and providers.
On occasion, we enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent, or other intellectual property infringement claim by any third-party with respect to its technology. The terms of these indemnification agreements are generally perpetual any time after the execution of the agreement. The maximum potential future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in the future but have not yet been made. Historically, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements.
We have entered into agreements with our directors or officers that may require us to indemnify them against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from their willful misconduct.
No liability associated with such indemnifications was recorded as of June 30, 2025 and December 31, 2024.
2. Summary of Significant Accounting Policies
Basis of Financial Statement Presentation
The financial statements include the consolidated balance sheets, statements of operations, statements of comprehensive income (loss), statements of changes in stockholders’ equity, and statements of cash flows of Waystar and its subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
The accompanying unaudited consolidated financial statements and notes have been prepared in accordance with GAAP and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the interim financial information includes all adjustments of a normal recurring nature necessary for a fair presentation of the Company’s financial position, results of operations, changes in stockholders’ equity and cash flows. The results of operations for the six months ended June 30, 2025 are not necessarily indicative of the results for the full year or the results for any future periods. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2024 in the 2024 Annual Report of Form 10-K filed with the SEC on February 18, 2025 (the “2024 Annual Report”).
7

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions are used for, but are not limited to: (1) revenue recognition, including estimated expected customer life; (2) recoverability of accounts receivable and taxes receivable; (3) impairment assessment of goodwill and long-lived intangible assets; (4) fair value of intangibles acquired in business combinations; (5) litigation reserves; (6) depreciation and amortization; (7) fair value of stock options issued to employees and assumed as part of business combinations; (8) fair value of interest rate swaps; and (9) leases, including incremental borrowing rate. Future events and their effects cannot be predicted with certainty, and accordingly, accounting estimates require the exercise of judgment. We evaluate and update assumptions and estimates on an ongoing basis and may employ outside experts to assist in evaluations. Actual results could differ from the estimates used.
Revenue Recognition
We derive revenue primarily from providing access to our solutions for use in the healthcare industry and in doing so generate two types of revenue: (i) subscription revenue and (ii) volume-based revenue, which account for 99% of total revenue for all periods presented. We also derive revenue from implementation fees for our software, as well as hardware sales to facilitate patient payments.
We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”), through the following five steps:
identification of the contract, or contracts, with a client;
identification of the performance obligations in the contract;
determination of the transaction price;
allocation of the transaction price to the performance obligations in the contract; and
recognition of revenue when, or as, we satisfy a performance obligation
Our customers, referred to as clients elsewhere in this report, represent healthcare providers across all types of care settings, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems.
We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. The length of our contracts vary but are typically two to three years and generally renew automatically for successive one-year terms. Our revenue is reported net of applicable sales and use tax and is recognized as, or when, control of these services or products are transferred to clients, in an amount that reflects the consideration we expect to be entitled to in exchange for the contract’s performance obligations.
Revenue from our subscription services as well as from our volume-based services represents a single promise to provide continuous access (i.e., a stand-ready obligation) to our software solutions in the form of a service. Our software products are made available to our clients via a cloud-based, hosted platform where our clients do not have the right or practical ability to take possession of the software. As each day of providing access to the software solutions is substantially the same and the client simultaneously receives and consumes the benefits as services are provided, these services are viewed as a single performance obligation comprised of a series of distinct daily services.
Revenue from our subscription services is recognized over time on a ratable basis over the contract term beginning on the date that the service is made available to the client. Volume-based services are priced based on transaction, dollar volume or provider count in a given period. Given the nature of the promise is based on unknown quantities or outcomes of services to be performed over the contract term, the volume-based fee is determined to be variable consideration. The volume-based transaction fees are recognized each day using a time- elapsed output method based on the volume or transaction count at the time the clients’ transactions are processed.
8

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Our other services are generally related to implementation activities across all solutions and hardware sales to facilitate patient payments. Implementation services are not considered performance obligations as they do not provide a distinct service to clients without the use of our software solutions. As such, implementation fees related to our solutions are billed upfront and recognized ratably over the customer's life. Implementation fees and hardware sales represent less than 1% of total revenue for all periods presented.
Our contracts with clients typically include various combinations of our software solutions. Determining whether such software solutions are considered distinct performance obligations that should be accounted for separately versus together requires significant judgment. Specifically, judgment is required to determine whether access to the Company’s SaaS solutions is distinct from other services and solutions included in an arrangement.
We follow the requirements of ASC 606-10-55-36 through -40, Revenue from Contracts with Customers, Principal Agent Considerations, in determining the gross versus net revenue presentations for our performance obligations in the contract with a client. Revenue recorded where we act in the capacity of a principal is reported on a gross basis equal to the full amount of consideration to which we expect in exchange for the good or service transferred. Revenue recorded where we act in the capacity of an agent is reported on a net basis, exclusive of any consideration provided to the principal party in the transaction.
The principal versus agent evaluation is a matter of judgment that depends on the facts and circumstances of the arrangement and is dependent on whether we control the good or service before it is transferred to the client or whether we are acting as an agent of a third party. This evaluation is performed separately for each performance obligation identified. For the majority of our contracts, we are considered the principal in the transaction with the client and recognize revenue gross of any related channel partner fees or costs. We have certain agency arrangements where third parties control the goods or services provided to a client and we recognize revenue net of any fees owed to these third parties.
Payment terms and conditions vary by contract type, although our standard payment terms generally require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from the timing of payment, we have determined our contracts do not generally include a significant financing component. The primary purpose of our invoicing terms is to provide clients with simplified and predictable ways of purchasing our products and services, not to receive financing from our clients or to provide clients with financing.
Contract Costs
Incremental Costs of Obtaining a Contract
Incremental costs of obtaining a contract primarily include commissions paid to our internal sales personnel. We consider all such commissions to be both incremental and recoverable since they are only paid when a contract is secured. These capitalized costs are amortized on a straight-line basis over the expected period of benefit, which is determined based on the average customer life, which includes anticipated renewals of contracts. As of June 30, 2025 and December 31, 2024, the total unamortized costs reported as deferred costs on our balance sheet amounted to $30.4 million and $29.0 million, respectively, for internal sales commissions. For the three months ended June 30, 2025 and 2024, amortization related to the sales commission asset was $3.2 million and $2.6 million, respectively. For the six months ended June 30, 2025 and 2024, amortization related to the sales commission asset was $6.3 million and $5.0 million, respectively. The aforementioned amortization amounts are included in sales and marketing in our consolidated statements of operations.
Costs to Fulfill a Contract
We capitalize costs incurred to fulfill contracts that i) relate directly to the contract, ii) are expected to generate resources that will be used to satisfy performance obligations under the contract, and iii) are expected to be recovered through revenue generated under the contract. Costs incurred to implement clients on our solutions (e.g., direct labor) are capitalized and amortized on a straight-line basis over the estimated customer life if we expect to recover those costs. As of June 30, 2025 and December 31, 2024, the total unamortized costs reported as deferred costs on our balance sheet amounted to $57.6 million and $53.8 million, respectively, for fulfillment costs. For the three months ended June 30, 2025 and 2024, amortization related to the fulfillment cost asset was $3.9 million and $3.0 million, respectively. For the six months ended June 30, 2025 and 2024, amortization related to the fulfillment cost asset was $7.6 million and $5.7 million,
9

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
respectively. The aforementioned amortization amounts are included in the costs of revenue in our consolidated statements of operations.
There were no impairment losses relating to deferred costs during the periods presented.
Channel Partners
We account for fees paid to channel partners within sales and marketing expenses in the accompanying statements of operations. For the three months ended June 30, 2025 and 2024, we recorded fees to all channel partners of $19.0 million and $16.1 million, respectively. For the six months ended June 30, 2025 and 2024, we recorded fees to all channel partners of $37.3 million and $30.6 million, respectively. As we are primarily responsible for contracting with and fulfilling contracts for the end user, we record revenue gross of related channel partner fees.
Cash and cash equivalents
We consider highly liquid investments with an original maturity of three months or less to be cash equivalents. We maintain our cash in bank deposit accounts, which, at times, may exceed federally insured limits. We have not experienced any credit losses in such accounts.

Investment securities
Our short-term investments, which consist of debt securities, are stated at fair value. These debt securities have been categorized as available-for-sale and classified as current assets given their maturity date is twelve months or less. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders’ equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of interest income/(expense) in the consolidated statements of income, the cost of investment securities sold is based upon specific identification.
Under the current expected credit losses model expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of any expected credit loss, only the amount of impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income. To the extent we have the intent to sell the debt security, or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.
There were no impairment losses relating to our investment securities during the periods presented.

Recently Issued Accounting Pronouncements Not Yet Adopted
In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Improvements to Income Tax Disclosures”, which requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities, the ASU will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. We are currently evaluating the effect of the adoption of this amendment on our consolidated and condensed consolidated financial statements.
In November 2024, the FASB issued ASU 2024-13, “Expense Disaggregation Disclosures.” The standard is intended to benefit investors by providing more detailed information about expenses that is critically important in understanding an
10

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
entity’s performance, assessing an entity’s prospects for future cash flows, and comparing an entity’s performance over time and with that of other entities. For public business entities, this ASU will be effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The amendments in this Update should be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this Update or (2) retrospectively to any or all prior periods presented in the financial statements. We are currently evaluating the effect of the adoption of this amendment on our consolidated financial statements.
3. Revenue Recognition
Disaggregation of Revenue
The following table presents revenues disaggregated by revenue type and the timing of revenue recognition (in thousands):
Three months ended June 30,Six months ended June 30,
Recognition2025202420252024
Subscription revenueOver time$131,108 $112,349 $256,149 $218,428 
Volume-based revenueOver time138,290 120,900 268,208 238,044 
Implementation services and other revenueVarious1,256 1,294 2,732 2,863 
Total revenues$270,654 $234,543 $527,089 $459,335 
Contract Liabilities
We derive our revenue from contracts with clients primarily through subscription fees and volume-based fees. Our payment terms with the client generally comprise an initial payment for implementation services, which includes client enrollment and the setup of contracted solutions on our platform. These implementation fees are due upon contract execution. Additionally, subscription fees are earned on an ongoing basis, which are invoiced monthly.
Client payments received in advance of fulfilling the corresponding performance obligations are recorded as contract liabilities. Implementation fees are recognized over the customer life, with any unrecognized amounts deferred as contract liabilities. These amounts are reported as deferred revenue on our consolidated balance sheet.
Revenue recognized from amounts included in deferred revenue as of the beginning of the period was $0.9 million and $0.8 million for the three months ended June 30, 2025 and 2024, respectively. Revenue recognized from the amounts included in deferred revenue as of the beginning of the period was $9.1 million and $9.5 million for the six months ended June 30, 2025 and 2024, respectively.
Transaction Price Allocated to Remaining Performance Obligations
At June 30, 2025, the transaction price related to unsatisfied performance obligations that are expected to be recognized for the next 12 months and greater than 12 months was $66.5 million and $13.9 million, respectively.
The transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts does not include revenue related to performance obligations that are part of a contract with an original expected duration of one year or less.
Additionally, the balance does not include variable consideration that is allocated entirely to wholly unsatisfied promises that form part of a single performance obligation comprised of a series of distinct daily services.
Remaining performance obligation estimates are subject to change and are affected by several factors, including terminations and changes in the timing and scope of contracts, arising from contract modifications.
11

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
4. Segments
Operating segments are defined as components of an enterprise about which separate financial information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. We have one business activity and there are no segment managers who are held accountable for operations, operating results and plans for products or components below the consolidated unit level. The geographical location of our customers has no impact on strategy or products offered. The “chief operating decision maker,” or CODM, assesses performance and allocates resources using a consolidated profitability metric as discussed below. Accordingly, we have determined that we operate in a single reportable operating segment.
Our CODM is our Chief Executive Officer. On a monthly basis, our CODM reviews the following financial information presented on a consolidated basis. The key profitability metric used for purposes of making key personnel staffing decisions, approving operating budgets and forecasts, and making strategy decisions is Net Income as detailed below. See Note 3 for our disaggregated revenue by type.
Three months ended June 30,Six months ended June 30,
($in thousands)2025202420252024
Total Revenue$270,654 $234,543 $527,089 $459,335 
Less:
Materials & connectivity62,271 56,814 122,724 110,998 
Labor & associated expenses24,773 23,637 47,665 44,645 
Research & development12,622 15,901 23,700 26,221 
Sales & marketing43,524 45,715 83,647 79,495 
General and administrative29,192 39,955 52,492 66,090 
Depreciation5,310 5,196 10,575 10,290 
Amortization28,116 39,080 56,231 78,160 
Interest and non-operating expenses, net18,255 50,541 37,155 107,725 
Income tax expense (benefit)14,407 (14,611)31,447 (20,672)
Segment Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
Consolidated Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
5. Investment Securities
The following table summarizes the unrealized positions for our investment securities classified as available-for-sale fixed-maturity debt securities, disaggregated by class of instrument (in thousands) as of June 30, 2025.
Amortized CostAllowances for Credit LossesTotal Unrealized GainsTotal Unrealized LossesFair Value
Available-for-sale fixed-maturity securities
Commercial Paper$24,185 $ $ $20 $24,165 
Corporate Notes10,105   6 10,099 
U.S. Treasury Bills11,204   1 11,203 
U.S. Government Agencies5,031   5 5,026 
Total$50,525 $ $ $32 $50,493 
The Company did not own any available-for-sale fixed-maturity securities as of December 31, 2024.
12

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
6. Fair Value Measurements and Disclosures
The following table presents the fair value hierarchy for financial assets and liabilities measured at fair value on a recurring basis (in thousands):
Balance Sheet ClassificationCarrying ValueLevel 1Level 2Level 3
June 30, 2025
Available-for-sale fixed-maturity securities
Commercial paperInvestment securities$24,185 $ $24,185 $ 
Corporate notesInvestment securities$10,105 $ $10,105 $ 
U.S. Treasury BillsInvestment securities$11,204 $ $11,204 $ 
U.S. Government AgenciesInvestment securities$5,031 $ $5,031 $ 
Money market fundsCash and cash equivalents$75 $75 $ $ 
Other financial assets:
Interest rate swapsOther current assets$788 $ $788 $ 
Other financial liabilities:
Interest rate swapsOther long-term liabilities$1,326 $ $1,326 $ 
December 31, 2024
Other financial assets:
Interest rate swapsOther current assets$1,127 $ $1,127 $ 
Interest rate swapsOther long-term assets$22 $ $22 $ 
The fair values of our interest rate swaps are based on the sum of all future net present value cash flows. The future cash flows are derived based on the terms of our interest rate swaps, as well as considering published discount factors, and projected SOFR curve. The fair value of long-term debt was determined using the present value of future cash flows based on the borrowing rates currently available for debt with similar terms and maturities. The carrying value of our first lien term loan facility was $1,157.7 million and $1,163.5 million compared to a fair value of $1,160.6 million and $1,169.4 million at June 30, 2025 and December 31, 2024, respectively. There were no transfers in or out of Level 3 during the periods presented.
As of June 30, 2025 and December 31, 2024, the carrying value of cash equivalents, accounts receivable, accounts payable, accrued liabilities, and other current assets and liabilities approximates fair value due to the short maturities of these instruments. Interest rate swaps are Level 2 instruments whose fair value is derived from discounted cash flows adjusted for nonperformance risk. Investment securities are Level 2 instruments whose fair value is observed through market data of similar securities. Money market funds are Level 1 instruments whose fair value is observed through daily quoted prices of similar assets. Money market funds are considered cash equivalents because they have a maturity of less than three months and are highly liquid.
13

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
7. Property and Equipment, Net
The balances of the major classes of property and equipment are as follows (in thousands):
June 30, 2025December 31, 2024
Computer hardware$41,357 $39,833 
Capitalized internal-use software47,014 40,281 
Purchased computer software22,938 22,789 
Furniture and fixtures3,841 3,642 
Office equipment266 247 
Leasehold improvements4,216 3,778 
Internal-use software in progress17,529 15,361 
137,161 125,931 
Accumulated depreciation(89,774)(79,200)
Total$47,387 $46,731 
Depreciation of fixed assets, including the amortization of capitalized software, for the three months ended June 30, 2025 and 2024 was $5.3 million and $5.2 million, respectively.
We capitalized $4.4 million and $8.9 million in software development costs for the three and six months ended June 30, 2025, respectively. We capitalized $4.0 million and $7.8 million in software developments costs for the three and six months ended June 30, 2024, respectively. Amortization of capitalized software was $3.4 million and $2.4 million for the three months ended June 30, 2025 and 2024, respectively, and was $6.8 million and $4.7 million for the six months ended June 30, 2025 and 2024, respectively. The net book value of capitalized software development costs was $31.7 million and $29.6 million as of June 30, 2025 and December 31, 2024, respectively.
There were no impairments of property and equipment for the three and six months ended June 30, 2025 and 2024, respectively.
8. Goodwill and Other Intangible Assets
Goodwill has a balance of $3,020.0 million as of both June 30, 2025 and December 31, 2024. There were no additions, disposals or impairments to goodwill during the three and six months ended June 30, 2025 and 2024.
Amortization for definite-lived intangible assets is as follows (in thousands, except useful life):
Gross Carrying
Amount
Accumulated
Amortization
Net
Carrying
Value
Weighted-
Average
Remaining
Useful Life
As of June 30, 2025
Customer relationships$1,429,400 $(488,170)$941,230 10.6
Purchased developed technology81,800 (57,470)24,330 4.2
Tradenames and trademarks40,700 (23,442)17,258 4.3
Total$1,551,900 $(569,082)$982,818 
As of December 31, 2024
Customer relationships$1,429,400 $(440,729)$988,671 11.1
Purchased developed technology81,800 (50,875)30,925 4.2
Tradenames and trademarks40,700 (21,247)19,453 4.7
Total$1,551,900 $(512,851)$1,039,049 
14

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Amortization expense was $28.1 million and $39.1 million for the three months ended June 30, 2025 and 2024, respectively and was $56.2 million and $78.2 million for the six months ended June 30, 2025 and 2024, respectively.
9. Leases
The following table presents components of lease expense for the three and six months ended June 30, 2025 and 2024, respectively (in thousands):
Three months ended June 30,Six months ended June 30,
2025202420252024
Finance lease cost
Amortization of right-of-use assets$ $397 $ $794 
Interest on lease liabilities177 189 177 382 
Operating lease cost1,132 860 2,271 1,773 
Variable lease cost111 109 1,266 151 
Short-term lease197 159 214 366 
Total lease cost$1,617 $1,714 $3,928 $3,466 
Maturities of lease liabilities as of June 30, 2025 are as follows (in thousands):
Operating LeasesFinance Leases
2025$3,112 $803 
20265,486 1,641 
20273,191 1,678 
20282,868 1,714 
20291,404 1,752 
Thereafter1,360 7,557 
Total future minimum lease payments17,421 15,145 
Less: Interest1,516 3,394 
Total$15,905 $11,751 
Supplemental cash flow information related to leases for the three and six months ended June 30, 2025 and 2024 are as follows (in thousands):
Three months ended June 30,Six months ended June 30,
2025202420252024
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases$1,615 $1,295 $3,229 $2,637 
Financing cash flows for financing leases535 394 935 785 
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases$ $594 $ $594 
15

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Supplemental balance sheet information related to leases as of June 30, 2025 and December 31, 2024 are as follows:
June 30, 2025December 31, 2024
Weighted average remaining lease term (years):
Operating leases3.84.1
Financing leases8.69.1
Weighted average discount rate:
Operating leases4.7 4.7 
Financing leases5.9 5.9 
10. Income Taxes
We recognized income tax expense of $14.4 million and income tax benefit of $14.6 million for the three months ended June 30, 2025 and 2024, respectively, based on the quarter-to-date pre-tax income. We recognized income tax expense of $31.4 million and income tax benefit of $20.7 million for the six months ended June 30, 2025 and 2024, respectively, based on the year-to-date pre-tax income. The Company’s effective income tax rate was 30.9% and 34.7% for the three months ended June 30, 2025 and 2024, respectively. The Company’s effective income tax rate was 33.9% and 32.2% for the six months ended June 30, 2025 and 2024, respectively. Differences in the effective tax rate and statutory federal income tax rate of 21% are primarily driven by the impact of certain limitations on the deductibility of stock-based compensation recognized for financial reporting purposes as well as state income taxes and research and development credits claimed.
11. Accounts Receivable Securitization
As of June 30, 2025 and December 31, 2024, we had $80.0 million and $80.0 million, respectively, outstanding under a receivables financing agreement with a counterparty as the lender, which provides for a three-year receivables facility with a limit of $80.0 million (the “Receivables Facility”). Pursuant to the Receivables Facility, we sell and/or contribute current and future receivables to Waystar RC, LLC as the Special Purpose Entity (“SPE”). The SPE, in turn, pledges its interests in the receivables to the counterparty, which either makes loans or issues letters of credit on behalf of the SPE. All receivables remain on our balance sheet as they continue to be the property of our consolidated entities under the securitization.
The interest rate under the Receivables Facility is 1.61% per annum above the SOFR rate with a minimum base of 0%. The SOFR is adjusted each thirty-day period to the thirty-day SOFR rate. Interest under the Receivables Facility is paid monthly in arrears. At June 30, 2025, the effective interest rate for the Receivables Facility is 5.94%.
All principal under the Receivables Facility is due on October 31, 2026.
The Receivables Facility contains certain covenants which, among other things, require we maintain certain collection thresholds with respect to our accounts receivable. We were in compliance with all such debt covenants during the periods presented.
16

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
12. Debt
Debt instruments consist primarily of term notes, revolving lines of credit, and a Receivables Facility as follows (in thousands):
June 30,December 31,
20252024
First lien term loan facility outstanding debt$1,157,712 $1,163,545 
Revolving credit facility  
Receivables facility outstanding debt80,000 80,000 
Total outstanding debt1,237,712 1,243,545 
Unamortized debt issuance costs(10,182)(11,255)
Current portion of long-term debt(11,668)(11,668)
Total long-term debt, net$1,215,862 $1,220,622 
The maturity of long-term principal payments (excluding debt discount) at June 30, 2025 is as follows (in thousands):
2025$5,835 
202691,668 
202711,668 
202811,668 
20291,116,873 
$1,237,712 
As of June 30, 2025 and December 31, 2024, there is no outstanding balance on our revolving credit facility. The interest rate under the revolving credit facility is 1.75% per annum above the SOFR rate with a minimum base of 0.00%. The SOFR is adjusted each thirty-day period to the thirty-day SOFR rate. At June 30, 2025, the effective interest rate for the revolving credit facility is 6.07%.
The interest rate under the amended First Lien Credit Facility is 2.25% per annum above the SOFR rate with a minimum base of 0.00%. The SOFR is adjusted each thirty-day period to the thirty-day SOFR rate. Interest under the First Lien Credit Facility is paid monthly in arrears. At June 30, 2025, the effective interest rate for First Lien Credit Facility is 6.82%.
Principal on the First Lien Credit Facility is payable in 20 equal quarterly installments with the remaining balance to be paid on October 22, 2029. As of June 30, 2025, there are 17 payments remaining. The First Lien Credit Agreement contains certain covenants which, among other things, restrict our ability to incur additional indebtedness. We were in compliance with such debt covenants as of June 30, 2025.
We had unamortized debt issuance costs of $10.2 million and $11.3 million as of June 30, 2025 and December 31, 2024, respectively.
In connection with the Revolving Credit Facility, unamortized debt issuance costs were $1.8 million and $2.1 million as of June 30, 2025 and December 31, 2024, respectively.
13. Derivative Financial Instruments
To mitigate the risk of a rise in interest rates on the First Lien Credit Facility, we entered into interest rate swaps on January 13, 2023, April 1, 2025 and April 9, 2025. We attempt to minimize our interest risk exposure by fixing our rate through the utilization of interest rate swaps, which are derivative instruments. The interest rate swaps mitigate the exposure on the variable component of interest on our First Lien Credit Facility. The interest rate swaps result in the fixed interest rate shown in the table below on the swapped portion of the First Lien Credit Facility. Our swaps are entered into with financial
17

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
institutions that participate in the First Lien Credit Facility. By using a derivative instrument to hedge exposures to changes in interest rates, we expose ourselves to credit risk due to the possible failure of the counterparty to perform under the terms of the derivative contract.
As of June 30, 2025 and December 31, 2024, we have the following interest rate swap agreements designated as a hedging instruments:
Effective DatesFloating Rate DebtFixed Rates
January 31, 2023 through January 31, 2026$506.7 million3.87 %
April 1, 2025 through January 30, 202680.0 million3.59 %
January 31, 2026 through March 31, 2027275.0 million3.59 %
January 31, 2026 through March 31, 2027275.0 million3.27 %
The gain or loss on the swaps is recognized in accumulated other comprehensive income/(loss) and reclassified into earnings as adjustments to interest expense in the same period or periods during which the swaps affect earnings. Gains or losses on the swaps representing hedge components excluded from the assessment of effectiveness are recognized in current earnings.
The effect of derivative instruments designated as hedging instruments on the accompanying consolidated financial statements is as follows (in thousands):
Derivatives - Cash Flow Hedging RelationshipsAmount of Gain or
(Loss) Recognized
in AOCI/AOCL on
Derivative
Location of Gain or
(Loss) Reclassified
from AOCI/AOCL
into Income
Amount of Gain or
(Loss) Reclassified
from AOCI/AOCL
into Income
Total Interest
Expense on
Consolidated
Statements of
Operations
Interest rate swaps:
Three months Ended June 30, 2025$(732)Interest expense$717 $(18,255)
Three months Ended June 30, 2024$(4,501)Interest expense$8,695 $(50,541)
Six Months Ended June 30, 2025$(1,288)Interest expense$1,289 $(37,155)
Six Months Ended June 30, 2024$(4,676)Interest expense$17,297 $(107,725)
The net amount of accumulated other comprehensive income expected to be reclassified to interest income in the next twelve months is $0.6 million.
14. Related Party Transactions
At June 30, 2025 and December 31, 2024, we had $56.2 million and $35.6 million, respectively, of outstanding debt as part of the First Lien Credit Facility from Bain Affiliated Funds and CPPIB Credit Investments III Inc., affiliates of Bain Capital LP and Canada Pension Plan Investment Board (“Affiliated Debtholders”). Interest expense associated with and paid to Affiliated Debtholders was $0.9 million and $1.3 million for the three months ended June 30, 2025 and 2024, respectively and $1.6 million and $2.7 million for the six months ended June 30, 2025 and 2024, respectively.
CPPIB has an ownership interest in us and a significant interest in the landlord that leases us office space under an operating lease agreement in Houston, Texas. For the three months ended June 30, 2025 and 2024, we expensed zero and $0.1 million, respectively, and for the six months ended June 30, 2025 and 2024, we expensed $0.0 million and $0.1 million, respectively, for this office space lease in general and administrative expense.
18

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Bain Capital LP has an ownership interest in us and a significant interest in some clients for whom we provide software solutions. For the three months ended June 30, 2025 and 2024, we earned revenue of $0.6 million from five clients and $0.4 from four clients, respectively. For the six months ended June 30, 2025 and 2024, we earned revenue of $1.2 million from five clients and $0.8 million from four clients, respectively. They also have an ownership interest in us and a significant interest in two vendors that provide us with software solutions. For the three months ended June 30, 2025 and 2024, we expensed $0.6 million and $0.1 million, respectively, and for the six months ended June 30, 2025 and 2024, we expensed $1.2 million and $0.2 million for software services from these vendors in cost of revenue expense.
15. Common and Preferred Stock
In connection with our initial public offering ("IPO") , the Company’s amended and restated certificate of incorporation became effective on June 10, 2024, which authorizes the issuance of 2,500,000,000 shares of common stock, par value $0.01 per share, and 100,000,000 shares of preferred stock, par value $0.01 per share. The shares of preferred stock have rights and preferences, including voting rights, designated from time to time by the Board of Directors. In connection with the amendment and restatement of the Company’s certificate of incorporation effective on the IPO date, the Class A common stock shares were automatically reclassified as, and became, one share of common stock. There were 174,146,070 and 172,108,240 common stock shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively.
16. Retirement Plans
We maintain qualified 401(k) plans which cover substantially all employees meeting certain eligibility requirements. Participants may contribute a portion of their compensation to the plans, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Under these plans, we contribute various percentages of employees’ salaries to the plans. Total expenses included in operating expenses in the accompanying consolidated statement of operations related to the plans were $1.3 million and $1.3 million for the three months ended June 30, 2025 and 2024 and $2.7 million and $2.4 million for the six months ended June 30, 2025 and 2024, respectively.
17. Stock-based Compensation
Equity incentive plans
On October 22, 2019, the Board of Directors approved the Waystar Holding Corp. 2019 Stock Incentive Plan (“2019 Waystar Holding Plan”). Under this plan, we can issue up to 9.9 million options or other equity awards. The granted awards contain service criteria, performance criteria, market conditions, or a combination thereof for vesting and have a 10-year contractual term. Options with a service condition generally vest over 5 years with 20% vesting in equal vesting installments. Options with a performance condition and a market condition vest based upon a change in control, initial public offering, or a sponsor distribution or deemed return if the investors have achieved specified levels of return on investment. In addition, as part of a change in control in 2019, 1.7 million fully vested rollover options remain outstanding.
The Board of Directors approved the Waystar Holding Corp. 2024 Equity Incentive Plan (the “2024 Equity Incentive Plan”), effective as of June 6, 2024, the date of pricing of our IPO. Under this plan, we can issue non-qualified stock options, incentive stock options, stock appreciation rights, restricted shares of the Company’s Common Stock, restricted stock units, performance based stock units, and other equity-based awards tied to the value of the Company’s shares. Under this plan, we can issue up to 10 million options and other equity awards, subject to annual increases as outlined under the plan. The number of shares available to be issued automatically increases on the first day of each fiscal year beginning next year by a number of shares equal to the lesser of the positive difference, if any, between 5% of the outstanding common stock on the last day of the immediately preceding fiscal year, minus the plan share reserve on the last day of the immediately preceding fiscal year or such lesser number of shares as may be determined by the Board of Directors. Options with a service condition generally vest over 5 years with 20% vesting in equal vesting installments. The restricted stock units (“RSUs”) under the 2024 Equity Incentive Plan generally vest over 4 or 5 years with 25% or 20% vesting, respectively, in equal vesting installments. The performance-based stock units (“PSUs”) under the 2024 Equity Incentive Plan vest between 0% and 200% based on the company's total shareholder return (TSR”) relative to a designated peer group as defined in the respective agreement over a four-year performance period. As of June 30, 2025, 5.5 million shares were available for future grants under this plan.
19

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
The Board of Directors approved the Waystar Holding Corp. 2024 Employee Stock Purchase Plan (the “ESPP”), effective as of June 6, 2024, the date of pricing of our IPO. A total of 3,250,000 shares of common stock are initially reserved for the ESPP. The number of shares available to be issued for the ESPP will automatically increase each fiscal year beginning next year by a number of shares equal to the lesser of the positive difference, if any, between 1% of the outstanding common stock on the last day of the immediately preceding fiscal year and the number of shares of common stock available for the issuance of shares pursuant to the plan on the last day of the immediately preceding fiscal year or such lesser number of shares as may be determined by the Board of Directors. The number of shares available to be issued for the ESPP will not exceed 27,000,000 as outlined in the plan agreement. Our employees contribute funds via payroll deductions during the offering periods, which are used to buy Waystar common shares at a discount of up to 15% of the purchase price at the purchase date. The initial offering period is March 1, 2025 through June 30, 2025 with the purchase date of June 30, 2025. For the three and six months ending June 30, 2025 and 2024, expense of $0.2 million and zero, respectively, has been recorded which represents the 15% discount given to the employees under the ESPP.

Stock Options
We utilize the Black-Scholes option pricing model to estimate the fair value of the service condition options under all plans and the Monte Carlo pricing model to estimate the fair value of the performance condition options under the 2019 Waystar Holding Corp. Plan. We value both types of options at the grant date using the following assumptions:
Risk-free interest rate—reflects the average rate on the United States Treasury bond with maturity equal to the expected term of the option;
Expected dividend yield—as we do not currently pay dividends or expect to pay dividends in the near future, the expected dividend yield is zero;
Expected term of stock award – under the 2024 Equity Incentive Plan, we utilized the simplified method due to the lack of historical experience activity for Waystar. The simplified method calculates the expected term as the mid-point between the vesting date and the contractual expiration date of the award. Under the 2019 Waystar Holding Corp. Plan, it is based on historical experience that is modified based on expected future changes;
Expected volatility in stock price—reflects the historical volatility of comparable public companies over the expected term of the stock option.
The weighted average grant date fair value of options granted during the three and six months ended June 30, 2025 was $18.69 per share. The weighted average grant date fair value of options granted during the three and six months ended June 30, 2024 was $12.59 per share and $12.89 per share, respectively. As of June 30, 2025, we had 7.0 million fully vested options with a weighted average exercise price of $14.43 per share, an aggregate intrinsic value of $185.7 million and an average remaining contractual term of 4.4 years. The total fair value of options vested for the three months ended June 30, 2025 and 2024 were $11.3 million and $0.5 million, respectively and $13.6 million and $1.8 million for the six months ending June 30, 2025 and 2024, respectively.
Information pertaining to option activity under all plans (including rollover options) during the six months ending June 30, 2025 and 2024 is as follows:
Number of
options
Weighted average
exercise price per
share
Weighted
average
remaining
contractual life
Outstanding December 31, 202416,511,128$17.57 5.8
Granted132,06536.94 
Exercised(1,577,468)9.55 
Forfeited(83,792)27.28 
Outstanding June 30, 202514,981,933$18.54 5.4
20

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Number of
options
Weighted average
exercise price per
share
Weighted
average
remaining
contractual life
Outstanding December 31, 202313,032,541$15.20 5.7
Granted4,003,70324.20 
Exercised(2,420)24.47 
Forfeited(58,564)17.68 
Outstanding June 30, 202416,975,260$17.31 6.3
The following is a summary of the significant assumptions used in estimating the fair value of options granted the three and six months ended June 30, 2025 and 2024:
Three months ended June 30,Six months ended June 30,
2025202420252024
Risk free interest rate3.95 %
4.24%-4.59%
3.95 %
3.76%-4.59%
Expected dividend yield0 %0 %0%0%
Expected term of stock award6.2
5.0-6.5
6.2
5.0 - 6.5
Expected volatility in stock price46.24 %
49.62%-51.73%
46.24 %
49.62%-51.89%
The aggregate intrinsic value of options exercised (the difference between the fair market value of our stock on the date of exercise and the exercise price) was approximately $23.9 million and $0.0 million for the three months ended June 30, 2025 and 2024, respectively and $48.9 million and $0.0 million for the six months ended June 30, 2025 and 2024, respectively.
We expect to incur compensation expense of approximately $45.4 million over a weighted average of 3.5 years for all unvested time-based awards outstanding on June 30, 2025.
RSUs
The RSUs granted on June 10, 2024 in conjunction with the IPO were valued at the IPO price. Subsequent RSU grants will be valued using our common stock price as of the grant date based on the publicly traded value per NASDAQ, and are expensed on a straight-line basis over the applicable vesting period. All vesting is contingent on continued service.
The following table summarizes RSU activity during the six months ended June 30, 2025 and 2024.
Number of
shares
Weighted
average grant
date fair value
Outstanding December 31, 20242,089,241$21.91 
Granted2,240,01737.38 
Vested(460,362)21.50 
Forfeited(48,350)27.38 
Outstanding June 30, 20253,820,546$30.96 
21

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Number of
shares
Weighted
average grant
date fair value
Outstanding December 31, 2023$ 
Granted2,011,65121.50 
Vested 
Forfeited(4,347)21.50 
Outstanding June 30, 20242,007,304$21.50 
We expect to incur compensation expense of $114.0 million over a weighted average of 4.6 years for all unvested RSUs outstanding on June 30, 2025.
PSUs
We utilize the Monte Carlo pricing model to estimate the fair value of the market-based condition PSUs at the grant date under the 2024 Equity Incentive Plan. The Monte Carlo model incorporates assumptions regarding expected volatility, correlation between performance of our stock price and that of publicly traded peer companies, expected dividend yields and the risk-free interest rate. The Monte Carlo pricing model simulates potential future stock price paths yielding a grant date fair value that reflects the likelihood of varying outcomes. These awards are expensed on a straight-line basis over the applicable vesting period utilizing the fair value at the grant date.
The following is a summary of the significant assumptions used in estimating the fair value of PSUs granted during the three and six months ended June 30, 2025. There were no PSUs granted prior to the six months ended June 30, 2025.
Three months ended June 30,Six months ended June 30,
2025202420252024
Risk free interest rate3.92 %N/A3.92 %N/A
Expected dividend yield0 %N/A0%N/A
Expected term of stock award4.0N/A4.0N/A
Expected volatility in stock price40.00 %N/A40.00 %N/A
The following table summarizes PSU activity during the six months ended June 30, 2025. There was no PSU activity prior to the six months ended June 30, 2025.
Number of
shares
Weighted
average grant
date fair value
Outstanding December 31, 2024$ 
Granted396,19761.67 
Vested 
Forfeited 
Outstanding June 30, 2025396,197$61.67 
We expect to incur compensation expense of $22.9 million over a weighted average of 3.8 years for all unvested PSUs outstanding on June 30, 2025.
Stock-based Compensation
We recorded $11.5 million and $37.0 million of stock-based compensation expense for the three months ended June 30, 2025 and 2024, respectively and $18.3 million and $39.5 million for the six months ended June 30, 2025 and 2024, respectively.
22

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
Stock-based compensation expense was recorded in the following cost and expense categories in the consolidated statements of operations:
Three months ended June 30,Six months ended June 30,
2025202420252024
Cost of revenue$415 $1,739 $646 $1,861 
General and administrative7,094 20,672 11,200 22,211 
Sales and marketing2,414 8,892 3,806 9,371 
Research and development1,607 5,666 2,622 6,054 
Total$11,530 $36,969 $18,274 $39,497 
18. Other Accrued Expenses
Other accrued expenses consist of the following (in thousands):
June 30, 2025December 31, 2024
Accrued income taxes$17,593 $4,111 
Other taxes payable4,184 3,915 
Accrued severance536  
Retirement plan payable651 497 
Accrued self insurance claims2,453 1,064 
Accrued interest630 597 
Accrued rent1,168  
ESPP payable1,560  
Other6,539 5,746 
Total$35,314 $15,930 
23

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
19. Income/ (Loss) Per Share
A reconciliation of the numerators and the denominators of the basic and diluted per share computations are as follows (in thousands, except for share and per share data):
Three months ended June 30,Six months ended June 30,
2025202420252024
Basic income/(loss) per share:
Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
Net income/(loss) attributable to common shares$32,184 $(27,685)$61,453 $(43,617)
Weighted average common stock outstanding–(voting)173,358,382133,527,766172,467,988127,601,532
Basic weighted average common stock outstanding173,358,382133,527,766172,467,988127,601,532
Basic income/(loss) per share$0.19 $(0.21)$0.36 $(0.34)
Diluted income/(loss) per share:
Net income/(loss)$32,184 (27,685)$61,453 (43,617)
Net income/(loss) attributable to common shares$32,184 $(27,685)$61,453 $(43,617)
Dilutive effect of stock options – (voting)7,096,1557,466,035
Dilutive effect of RSUs – (voting)1,140,8501,139,670
Dilutive effect of ESPP – (voting)3,7462,456
Weighted average common stock outstanding–(voting)181,599,133133,527,766181,076,149127,601,532
Diluted weighted average common stock outstanding181,599,133133,527,766181,076,149127,601,532
Diluted income/(loss) per share$0.18 $(0.21)$0.34 $(0.34)
Because of their anti-dilutive effect, 1,381,263 and 3,766,890 common share equivalents comprised of stock options and RSUs have been excluded from the diluted earnings per share calculation for the three months ended June 30, 2025 and 2024, respectively. Additionally because of their anti-dilutive effect, 1,125,049 and 3,731,340 common share equivalents comprised of stock options and RSUs have been excluded from diluted earnings per share calculation for the six months ended June 30, 2025 and 2024, respectively.
20. Commitments and Contingencies
We may be subject to legal proceedings, claims, asserted or unasserted, and litigation arising in the ordinary course of business. We do not, however, currently expect that the ultimate costs to resolve any pending matter will have a material effect on our consolidated financial position, results of operations, or cash flows.
21. Subsequent Events
We have evaluated subsequent events through the date of issuance.
On July 4, 2025, H.R.1, the budget reconciliation bill known as the “One Big Beautiful Bill Act”, was signed into law in the U.S. This legislation includes significant changes to U.S. tax law impacting corporate tax rates, bonus depreciation, interest limitations under Internal Revenue Code Section 163(j), and the treatment of domestic research and development expenditures. We are currently evaluating the effect of this legislation on our consolidated and condensed consolidated financial statements. As the legislation was signed into law after the close of our second quarter, the impacts are not included in our operating results for the six months ended June 30, 2025.
On July 23, 2025, we entered into an Agreement and Plan of Merger to acquire Iodine through a series of mergers. The acquisition, valued at $1.25 billion, includes $625.0 million in cash and 16,751,541 shares of common stock. The consummation of the acquisition is subject to the satisfaction of customary closing conditions. Given the acquisition has yet to close, accounting conclusions related to the transaction are pending.
24

Table of Contents
Waystar Holding Corp.
Notes to Unaudited Condensed Consolidated Financial Statements
No other significant subsequent events have occurred through the date of issuance.
25

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of Waystar Holding Corp. (“Waystar”, the “Company”, “we”, “us”, and “our”) financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and the related notes included elsewhere in this Form 10-Q, and the consolidated financial statements and related notes included in the 2024 Form 10-K. In addition to historical information, this discussion and analysis contains forward-looking statements based on current expectations that involve risks, uncertainties, and other factors outside the Company’s control, as well as assumptions, such as our plans, objectives, expectations, and intentions. Our actual results may differ materially from those expressed or implied in the forward-looking statements as a result of various factors, including those described under the sections entitled “Cautionary Statement Concerning Forward-Looking Statements” above and “Risk Factors” in the 2024 Form 10-K and our other filings with the SEC.
Overview
Waystar provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. Our enterprise-grade platform streamlines the complex and disparate processes our healthcare provider clients must manage to be reimbursed correctly, while improving the payments experience for providers, patients, and payers. We leverage AI as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers.
Our software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. We currently serve over 30,000 clients of various sizes, representing over one million distinct providers practicing across a variety of care sites, including 16 of the top 20 U.S. News Best Hospitals. Our business model is designed such that as our clients grow to serve more patients, their claims and transactional volumes increase, resulting in corresponding growth in our business. In addition, our clients frequently adopt a greater number of our solutions over time and introduce our solutions across new sites of care. In 2024, we facilitated over six billion healthcare payments transactions, including over $1.8 trillion in gross claims volume. As of 2024, we facilitated healthcare payments transactions spanning approximately 50% of patients in the United States.
Our platform benefits from powerful network effects. Our cloud-based software is driven by a sophisticated, automated, and curated rules engine, employing AI to generate and incorporate real-time feedback from millions of network transactions processed through our platform each day. Every transaction we process provides additional data insights across providers, patients, and payers, which are embedded in updates that are deployed efficiently across our client base. This results in cumulative benefits to us over time —as we capture more data from each transaction we process, we leverage that data to continue to improve the Waystar platform through embedded machine learning, advanced algorithms, and other in-house AI technologies to deliver added value to our clients. In turn, the more value we create for our clients, the more likely it is that they will continue to use our products, allowing us to continue to capture more data that results in tangible improvements to our platform. As a result, our clients benefit from faster and more efficient performance from software that is evolving to meet ever-changing regulatory and payer requirements, enabling accurate and timely reimbursement.
We have demonstrated an ability to drive recurring, predictable, and profitable growth. Over 99% of our revenue is either recurring subscription or based on highly predictable volumes. For the twelve months ended June 30, 2025, our Net Revenue Retention Rate was 114.6% and we have 1,268 clients as of June 30, 2025 generating over $100,000 over the same twelve month period. For the six months ended June 30, 2025, we generated revenue of $527.1 million (reflecting a 14.8% increase compared to revenue of $459.3 million for the same period in the prior year), net income of $61.5 million compared to net loss of $43.6 million for the same period in the prior year, and Adjusted EBITDA of $220.3 million (reflecting a 18.0% increase compared to Adjusted EBITDA of $186.7 million for the same period in the prior year).
Initial Public Offering
In June 2024, we completed an initial public offering (the “IPO”) of 45,000,000 shares of common stock at a price of $21.50 per share. After underwriting discounts and commissions of $53.2 million, we received total proceeds from the offering of $914.3 million. On July 5, 2024, pursuant to the option granted to the underwriters for a period of 30 days from the date of the IPO Prospectus to purchase up to 6,750,000 additional shares of common stock from us at the IPO price less the underwriting discount, the underwriters exercised the right to purchase 5,059,010 additional shares of common stock, resulting in additional net proceeds of $102.8 million, after deducting underwriting discounts and commissions of $6.0
26

Table of Contents
million. The remaining option to purchase additional shares expired unexercised at the end of the 30-day period. See Item 1, Financial Statements, Note 1 (Business) in the 2024 Form 10-K for more information.
Secondary Offerings
On February 24, 2025, the Institutional Investors closed an underwritten public offering of 23,000,000 shares of our common stock (inclusive of the underwriters’ option to purchase additional shares) (the “First Secondary Offering”). Additionally on May 15, 2025, the Institutional Investors closed another underwritten public offering of 14,375,000 shares of our common stock (inclusive of the underwriters' option to purchase additional shares) (the "Second Secondary Offering"). The Company did not sell any shares in these offerings or receive any proceeds from these offerings. Pursuant to the terms of the Amended and Restated Registration Rights Agreement, dated as of June 10, 2024, by and among the Company, the Institutional Investors, and certain other parties thereto, we paid $1.8 million and $3.2 million in certain expenses on behalf of the selling stockholders related to these offerings for the three and six months ended June 30, 2025, respectively, while the selling stockholders paid all applicable underwriting discounts and commissions.
Iodine Acquisition
On July 23, 2025, we entered into an Agreement and Plan of Merger to acquire Iodine through a series of mergers. The acquisition, valued at $1.25 billion, includes $625.0 million in cash and 16,751,541 shares of common stock. Iodine is a trusted leader in AI-powered clinical intelligence, enhancing clinical documentation and accuracy, streamlining utilization management, and preventing revenue leakage before billing. This strategic move is expected to bolster our AI leadership, automate manual work, and improve financial performance for providers. The boards of both companies have approved the merger, which is subject to customary closing conditions and regulatory approvals. The acquisition is expected to close by year-end 2025.
Significant Items Affecting Comparability
We believe that the future growth and profitability of our business, and the comparability of our results from period to period, depend on numerous factors, including the following:
Our Ability to Expand our Relationship with Existing Clients
As our clients grow their businesses and provide more services and see more patients, our volume-based revenues also increase. In addition, our growth in revenues also depends on our ability to sell more products and solutions to existing clients, including through cross-selling as our clients adopt additional Waystar offerings as well as up-selling as our clients leverage our solutions across additional providers and sites of care.
Our Ability to Grow our Client Base
We are focused on continuing to grow our client base, which will depend in part on our ability to continue to maintain our product leadership, invest in our research and development team, and maintain our reputation and brand.
Impacts of the IPO
Debt Repayment. We used proceeds from our IPO to repay an aggregate of $1.0 billion in outstanding principal amount on our First Lien Credit Facility in the second and third quarters of fiscal 2024. This debt repayment has contributed to lower interest expense for the three and six months ended June 30, 2025 compared to the same periods in the prior year.
Stock-Based Compensation Expenses. We expect to recognize stock-based compensation expense of $17.9 million per year over the applicable vesting periods in connection with equity awards granted in connection with the IPO. Such stock-based compensation expense will be reflected in our results of operations from the closing date of the IPO through the applicable vesting periods of such awards. Additionally, we recognized $33.1 million of stock-based compensation expense during the three months ended June 30, 2024, as the vesting of our performance condition options became probable upon the closing of the IPO as the implicit service period for the awards established at the grant date had elapsed.
27

Table of Contents
Incremental Public Company Expenses. Following the IPO, we have incurred significant expenses on an ongoing basis that we did not incur as a private company. Those costs include additional director and officer liability insurance expenses, as well as third-party and internal resources related to accounting, auditing, Sarbanes-Oxley Act compliance, legal, and investor and public relation expenses. These costs are generally expensed under general and administrative expenses.
Components of Results of Operations
Revenue
We primarily generate two types of revenue: (i) subscription revenue and (ii) volume-based revenue, which account for 99% of total revenue for all periods presented. We believe we have high visibility into our volume-based and subscription revenue from existing clients. We refer to the solutions our clients use to better process and understand their payment workflows from payers as provider solutions, and we refer to the products that assist healthcare providers in collecting payments from patients as patient payment solutions. We expect provider solutions will continue to generate the substantial majority of our total revenue, although the revenue mix attributable to patient payment solutions is expected to increase slightly over time.
Subscription revenue. Reflects recurring monthly provider count fees and minimum amounts owed. The vast majority of subscription revenue is generated by provider solutions, which constituted approximately 70% of total revenue in each of the three and six months ended June 30, 2025 and 2024.
Volume-based revenue. Represents recurring fees associated with transaction count or dollar volumes in excess of minimums. Generally, approximately half of our volume-based revenue is generated from provider solutions that are based on transaction count, with the other half from patient payments solutions that are based on either dollar volumes or transaction count.
We also derive revenue from implementation fees for our software, as well as hardware sales to facilitate patient payments. Our implementation fees are billed upfront and the revenue is recognized ratably over the customer's life.
Cost of Revenue (Exclusive of Depreciation and Amortization)
Cost of revenue includes salaries, stock-based compensation, and benefits (“personnel costs”) for our team members who are focused on implementation, support, and other client-focused operations, as well as team members focused on enhancing and developing our platform. Cost of revenue also includes costs for third-party technology such as interchange fees and infrastructure related to the operations of our platform, including communicating and processing patient payments, and services to support the delivery of our solutions. Third-party costs for patient payments solutions are approximately 60% of the revenue generated from these solutions, while third-party costs for provider solutions are approximately 6% to 8% of the associated revenue, in each case, for both the three and six months ended June 30, 2025 and 2024.
Sales and Marketing
Sales and marketing costs consist primarily of personnel costs, internal sales commissions, channel partner fees, travel, and advertising costs.
General and Administrative
General and administrative expenses consist of personnel costs incurred in our corporate service functions such as finance expenses, legal, human resources, and information technology, as well as other professional service costs.
Research and Development
Research and development costs consist primarily of personnel costs for team members engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred, except for capitalized software development costs.
28

Table of Contents
Depreciation and Amortization
Depreciation and amortization consists of the depreciation of property and equipment and amortization of certain intangible assets, including capitalized software.
Other Expense
Other expense consists primarily of interest expense and related-party interest expense, inclusive of the impact of interest rate swaps and net of interest income.
Income Tax Expense/(Benefit)
Income tax expense/(benefit) includes current income tax and income tax credits from deferred taxes. Income tax expense/benefit is recognized in profit and loss except to the extent that it relates to items recognized in equity or other comprehensive income, in which case the income tax expense/(benefit) is also recognized in equity or other comprehensive income.
Results of Operations for the Three Months Ended June 30, 2025 and 2024
The following table provides consolidated operating results for the periods indicated and percentage of revenue for each line item:
Three months ended June 30,
20252024Change
($ in thousands)($)(%)($)(%)($)(%)
Revenue$270,654 100.0 %$234,543 100.0 %$36,111 15.4 %
Operating expenses
Cost of revenue (exclusive of depreciation and amortization)87,044 32.2 %80,451 34.3 %6,593 8.2 %
Sales and marketing43,524 16.1 %45,715 19.5 %(2,191)(4.8)%
General and administrative29,192 10.8 %39,955 17.0 %(10,763)(26.9)%
Research and development12,622 4.7 %15,901 6.8 %(3,279)(20.6)%
Depreciation and amortization33,426 12.4 %44,276 18.9 %(10,850)(24.5)%
Total operating expenses205,808 76.0 %226,298 96.5 %(20,490)(9.1)%
Income from operations64,846 24.0 %8,245 3.5 %56,601 686.5 %
Other expense
Interest expense(17,325)(6.4)%(49,195)(21.0)%31,870 (64.8)%
Related party interest expense(930)(0.3)%(1,346)(0.6)%416 (30.9)%
Income/(loss) before income taxes46,591 17.2 %(42,296)(18.0)%88,887 NM
Income tax expense/(benefit)14,407 5.3 %(14,611)(6.2)%29,018 NM
Net income/(loss)$32,184 11.9 %$(27,685)(11.8)%$59,869 NM
Revenue
Three months ended June 30,
20252024Change
($ in thousands)($)(%)($)(%)($)(%)
Revenue
Subscription revenue$131,108 48.4 %$112,349 47.9 %$18,759 16.7 %
Volume-based revenue138,290 51.1 %120,900 51.5 %17,390 14.4 %
Services and other revenue1,256 0.5 %1,294 0.6 %(38)(2.9)%
Total Revenue$270,654 100.0 %$234,543 100.0 %$36,111 15.4 %
29

Table of Contents
Revenue was $270.7 million for the three months ended June 30, 2025 as compared to $234.5 million for the three months ended June 30, 2024, an increase of $36.1 million, or 15.4%, of which $18.8 million was attributed to subscription revenue from new and existing clients, almost all of which was generated by provider solutions. Another $17.4 million was attributed to volume-based revenue primarily related to expansion of existing client usage, of which $11.2 million was generated by patient payments solutions and $6.2 million was generated by provider solutions.
Cost of Revenue (Exclusive of Depreciation and Amortization)
Cost of revenue was $87.0 million for the three months ended June 30, 2025 as compared to $80.5 million for the three months ended June 30, 2024, an increase of $6.6 million, or 8.2%. The increase was primarily driven by $5.5 million in increased costs stemming from higher transaction volumes and associated third-party costs, including higher platform usage, of which approximately $6.9 million was from costs associated with payment solutions offset by a decrease of $1.5 million from costs associated with provider solutions, primarily from timing of prior acquisition synergy attainment.
Sales and Marketing
Sales and marketing expense was $43.5 million for the three months ended June 30, 2025 as compared to $45.7 million for the three months ended June 30, 2024, a decrease of $2.2 million, or 4.8%. The decrease was primarily driven by stock-based compensation expense of $6.5 million attributable to the recognition of performance condition options that did not recur during the three months ended June 30, 2025 (see “Impacts of IPO” section above), offset by an increase in channel partner fees and amortization of the internal commission deferred contract costs asset of $3.5 million associated with revenue growth and increased personnel costs of $1.2 million.
General and Administrative
General and administrative expense was $29.2 million for the three months ended June 30, 2025 as compared to $40.0 million for the three months ended June 30, 2024, a decrease of $10.8 million, or 26.9%. The decrease was primarily due to a reduction in stock-based compensation expense of $13.6 million attributable to the recognition of performance condition options that did not recur during the three months ended June 30, 2025 (see “Impacts of IPO” section above).
Research and Development
Research and development expense was $12.6 million for the three months ended June 30, 2025 as compared to $15.9 million for the three months ended June 30, 2024, a decrease of $3.3 million, or 20.6%. The decrease was primarily due to a reduction in stock-based compensation expense of $4.1 million attributable to the recognition of performance condition options that did not recur during the three months ended June 30, 2025 (see “Impacts of IPO” section above).
Depreciation and Amortization
Depreciation and amortization expense was $33.4 million for the three months ended June 30, 2025, as compared to $44.3 million for the three months ended June 30, 2024, a decrease of $10.9 million, or 24.5%. The decrease was due to several intangible assets becoming fully amortized in the prior year, driving a decrease in intangible amortization.
Interest Expense
Total interest expense was $18.3 million for the three months ended June 30, 2025 as compared to $50.5 million for the three months ended June 30, 2024, a decrease of $32.3 million, or 63.9%. $27.6 million of the decrease, net of the impact of interest rate swaps, was driven by First Lien Credit Facility paydowns during 2024 totaling $1.0 billion.
Income Tax Expense/(Benefit)
Income tax expense was $14.4 million for the three months ended June 30, 2025, as compared to an income tax benefit of $14.6 million for the three months ended June 30, 2024, an increase of $29.0 million. The increase was primarily driven by the increase in pre-tax income/(loss).
30

Table of Contents
Results of Operations for the Six Months Ended June 30, 2025 and 2024
The following table provides consolidated operating results for the periods indicated and percentage of revenue for each line item:
Six months ended June 30,
20252024Change
($ in thousands)($)(%)($)(%)($)(%)
Revenue$527,089 100.0 %$459,335 100.0 %$67,754 14.8 %
Operating expenses
Cost of revenue (exclusive of depreciation and amortization)170,389 32.3 %155,643 33.9 %14,746 9.5 %
Sales and marketing83,647 15.9 %79,495 17.3 %4,152 5.2 %
General and administrative52,492 10.0 %66,090 14.4 %(13,598)(20.6)%
Research and development23,700 4.5 %26,221 5.7 %(2,521)(9.6)%
Depreciation and amortization66,806 12.7 %88,450 19.3 %(21,644)(24.5)%
Total operating expenses397,034 75.3 % ` 415,899 90.5 %(18,865)(4.5)%
Income from operations130,055 24.7 %43,436 9.5 %86,619 199.4 %
Other expense
Interest expense(35,582)(6.8)%(105,007)(22.9)%69,425 (66.1)%
Related party interest expense(1,573)(0.3)%(2,718)(0.6)%1,145 (42.1)%
Income/(loss) before income taxes92,900 17.6 %(64,289)(14.0)%157,189 NM
Income tax expense/(benefit)31,447 6.0 %(20,672)(4.5)%52,119 NM
Net income/(loss)$61,453 11.7 %$(43,617)(9.5)%$105,070 NM
Revenue
Six months ended June 30,
20252024Change
($ in thousands)($)(%)($)(%)($)(%)
Revenue
Subscription revenue$256,149 48.6 %$218,428 47.6 %$37,721 17.3 %
Volume-based revenue268,208 50.9 %238,044 51.8 %30,164 12.7 %
Services and other revenue2,732 0.5 %2,863 0.6 %(131)(4.6)%
Total Revenue$527,089 100.0 %$459,335 100.0 %$67,754 14.8 %
Revenue was $527.1 million for the six months ended June 30, 2025 as compared to $459.3 million for the six months ended June 30, 2024, an increase of $67.8 million, or 14.8%, of which $37.7 million was attributed to subscription revenue from new and existing clients, almost all of which is generated by provider solutions. Another $30.2 million was attributed to volume-based revenue primarily related to expansion of existing client usage, most of which was generated by patient payments solutions.
Cost of Revenue (Exclusive of Depreciation and Amortization)
Cost of revenue was $170.4 million for the six months ended June 30, 2025 as compared to $155.6 million for the six months ended June 30, 2024, an increase of $14.7 million, or 9.5%. The increase was primarily driven by $11.7 million in increased costs stemming from higher transaction volume and associated third-party costs, including higher platform usage, of which approximately $15.5 million was from costs associated with payment solutions offset by a decrease of $3.8 million from costs associated with provider solutions, primarily from timing of prior acquisition synergy attainment.
31

Table of Contents
Sales and Marketing
Sales and marketing expense was $83.6 million for the six months ended June 30, 2025 as compared to $79.5 million for the six months ended June 30, 2024, an increase of $4.2 million, or 5.2%. The increase was primarily driven by an increase in channel partner fees and amortization of the internal commission deferred contract costs asset of $8.0 million associated with revenue growth and increased personnel costs of $2.2 million. This was offset by a decrease in stock-based compensation of $5.6 million attributable to the recognition of performance condition options that did not recur during the six months ended June 30, 2025 (see “Impacts of IPO” section above).
General and Administrative
General and administrative expense was $52.5 million for the six months ended June 30, 2025 as compared to $66.1 million for the six months ended June 30, 2024, a decrease of $13.6 million, or 20.6%. The decrease was primarily due to a reduction in stock-based compensation expense of $11.0 million attributable to the recognition of performance condition options that did not recur during the six months ended June 30, 2025 (see “Impacts of IPO” section above).
Research and Development
Research and development expense was $23.7 million for the six months ended June 30, 2025 as compared to $26.2 million for the six months ended June 30, 2024, a decrease of $2.5 million, or 9.6%. The decrease was primarily driven by a decrease in stock-based compensation expense of $3.4 million attributable to the recognition of performance condition options that did not recur during the six months ended June 30, 2025 (see “Impacts of IPO” section above).
Depreciation and Amortization
Depreciation and amortization expense was $66.8 million for the six months ended June 30, 2025, as compared to $88.4 million for the six months ended June 30, 2024, a decrease of $21.6 million, or 24.5%. The decrease was due to several intangible assets becoming fully amortized in the prior year, driving a decrease in intangible amortization.
Interest Expense
Total interest expense was $37.2 million for the six months ended June 30, 2025 as compared to $107.7 million for the six months ended June 30, 2024, a decrease of $70.6 million, or 65.5%. The decrease was driven by the paydowns during 2024 totaling $1.0 billion on our First Lien Credit Facility decreasing the corresponding interest expense.
Income Tax Benefit
Income tax expense was $31.4 million for the six months ended June 30, 2025 as compared to an income tax benefit of $20.7 million for the six months ended June 30, 2024, an increase of $52.1 million. The increase was primarily driven by the increase in pre-tax income/(loss).
Non-GAAP Financial Measures
We present adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income/(loss), and non-GAAP net income/(loss) per share as supplemental measures of financial performance that are not required by, or presented in accordance with, GAAP. We believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate, and capital investments. Management uses these to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation, and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone provide.
Adjusted EBITDA, adjusted EBITDA margin, non-GAAP net income / (loss), and non-GAAP net income / (loss) per share are not recognized terms under GAAP and should not be considered as an alternative to net income (loss) or net income (loss) margin as measures of financial performance or cash provided by operating activities as a measure of liquidity, or
32

Table of Contents
any other performance measure derived in accordance with GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management’s discretionary use, as they do not consider certain cash requirements such as interest payments, tax payments, and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company. A reconciliation is provided below for our non-GAAP financial measures to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA and Adjusted EBITDA Margin
We define adjusted EBITDA as net income / (loss) before interest expense, net, income tax expense / (benefit), depreciation and amortization, and as further adjusted for stock-based compensation expense, acquisition and integration costs, asset and lease impairments, costs related to amended debt agreements, and costs related to our IPO and the Secondary Offerings. Adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
The following table presents a reconciliation of net income/(loss) to adjusted EBITDA and net income/(loss) margin to adjusted EBITDA margin for the three months ended June 30, 2025 and 2024:
Three months ended June 30,Six months ended June 30,
($ in thousands)2025202420252024
Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
Interest expense18,255 50,541 37,155 107,725 
Income tax expense/(benefit)14,407 (14,611)31,447 (20,672)
Depreciation and amortization33,426 44,276 66,806 88,450 
Stock-based compensation expense11,530 36,969 18,274 39,497 
Acquisition and integration costs655 206 884 508 
Costs related to amended debt agreements— 2,368 — 12,770 
IPO related and Secondary Offering expenses1,769 1,841 3,199 2,005 
Other (a)326 — 1,080 — 
Adjusted EBITDA$112,552 $93,905 $220,298 $186,666 
Revenue$270,654 $234,543 $527,089 $459,335 
Net income/(loss) margin11.9 %(11.8)%11.7 %(9.5)%
Adjusted EBITDA margin41.6 %40.0 %41.8 %40.6 %
_______________________________________________________________
(a)Adjustments relate to additional lease costs due to the relocation of our Louisville office totaling $0.2 million and $0.4 million, respectively, and executive severance totaling $0.0 million and $0.5 million, respectively, for the three and six months ended June 30, 2025.
Non-GAAP Net Income / (Loss) and Non-GAAP Net Income / (Loss) Per Share
We define non-GAAP net income as GAAP net income / (loss) excluding the impact of stock-based compensation, acquisition and integration costs, asset and lease impairments, costs related to our IPO, and the Secondary Offerings, and costs related to amended debt agreements and amortization of intangibles. The tax effects of the adjustments are calculated using a management estimated annual effective non-GAAP tax rate of 21%, which is based on our statutory federal tax rate and provides consistency across interim reporting periods by eliminating the effects of non-recurring and period specific items. Due to the differences in the tax treatment of items excluded from non-GAAP net income, our estimated tax rate on non-GAAP net income may differ from our GAAP tax rate.
Non-GAAP net income per share is shown on both a basic and diluted basis and is defined as non-GAAP net income divided by the basic or diluted weighted-average shares, respectively.

33

Table of Contents
The following table presents a reconciliation of net loss to non-GAAP net income / (loss) and non-GAAP net income / (loss) per share for the three and six months ended June 30, 2025 and 2024:
Three months ended June 30,Six months ended June 30,
($ in thousands)2025202420252024
Net income/(loss)$32,184 $(27,685)$61,453 $(43,617)
Stock based compensation11,530 36,969 18,274 39,497 
Acquisition and integration costs655 206 884 508 
Costs related to amended debt agreements— 2,368 — 12,770 
IPO and Secondary Offering expenses1,769 1,841 3,199 2,005 
Other (a)326 — 1,080 — 
Intangible amortization28,115 39,080 56,230 78,160 
Tax effect of adjustments(8,903)(16,897)(16,730)(27,917)
Non-GAAP net income/(loss)$65,676 $35,882 $124,390 $61,406 
Non-GAAP net income/(loss) per share:
Basic$0.38 $0.27 $0.72 $0.48 
Diluted$0.36 $0.26 $0.69 $0.47 
Weighted-average shares outstanding:
Basic173,358,382 133,527,766 172,467,988 127,601,532 
Diluted181,599,133 137,294,656 181,076,149 131,332,872 
(a)Adjustments relate to additional lease costs due to the relocation of our Louisville office totaling $0.2 million and $0.4 million, respectively, and executive severance totaling $0.0 million and $0.5 million, respectively, for the three and six months ended June 30, 2025.
Key Performance Metrics
Net Revenue Retention Rate
We also regularly monitor and review our Net Revenue Retention Rate.
The following table presents our Net Revenue Retention Rate for June 30, 2025 and 2024, respectively:
Twelve months ended June 30,
($in thousands)20252024
Net Revenue Retention Rate114.6 %107.5 %
Our Net Revenue Retention Rate compares twelve months of client invoices for our solutions at two period end dates. To calculate our Net Revenue Retention Rate, we first accumulate the total amount invoiced during the twelve months ending with the prior period-end, or Prior Period Invoices. We then calculate the total amount invoiced to those same clients for the twelve months ending with the current period-end, or Current Period Invoices. Current Period Invoices are inclusive of upsell, downsell, pricing changes, clients that cancel or chose not to renew, and discontinued solutions with continuing clients. The Net Revenue Retention Rate is then calculated by dividing the Current Period Invoices by the Prior Period Invoices. Our total invoices included in the analysis are greater than 98% of reported revenue. We use Net Revenue Retention Rate to evaluate our ongoing operations and for internal planning and forecasting purposes. Acquired businesses are included in the last-twelve month Net Revenue Retention Rate in the ninth quarter after acquisition, which is the earliest point that comparable post-acquisition invoices are available for both the current and prior twelve-month period.
Customer Count with >$100,000 Revenue
We also regularly monitor and review our count of clients who generate more than $100,000 of revenue.
The following table sets forth our count of clients who generate more than $100,000 of revenue for the periods presented:
34

Table of Contents
Twelve months ended June 30,
20252024
Customer Count with > $100,000 Revenue1,268 1,117 
Our count of clients who generate more than $100,000 of revenue is based on an accumulation of the amounts invoiced to clients over the preceding twelve months. The invoices for acquired clients are included starting in the first full calendar quarter after the date of acquisition.
Liquidity and Capital Resources
Overview
We assess our liquidity in terms of our ability to generate adequate amounts of cash to meet current and future needs. Our expected primary uses on a short-term and long-term basis are for working capital, capital expenditures, debt service requirements, and investments in future growth, including acquisitions. We have historically funded our operations and acquisitions through our cash and cash equivalents, cash flows from operations, and debt financings. We believe that our existing unrestricted cash on hand, expected future cash flows from operations, and additional borrowings will provide sufficient resources to fund our operating requirements, as well as future capital expenditures, debt service requirements, and investments in future growth for at least the next 12 months. To the extent additional funds are necessary to meet our long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of additional indebtedness, additional equity financings, or a combination of these potential sources of funds. In the event that we need access to additional cash, we may not be able to access the credit markets on commercially acceptable terms or at all. Our ability to fund future operating expenses and capital expenditures and our ability to meet future debt service obligations or refinance our indebtedness will depend on our future operating performance, which will be affected by general economic, financial, and other factors beyond our control, including those described under “Risk factors” in the 2024 Form 10-K.
On June 30, 2025 and December 31, 2024, we had restricted cash of $21.2 million and $22.4 million, respectively, which consists of cash deposited in lockbox accounts owned by us which are contractually required to be disbursed to participating clients on the following day, as well as cash collected on behalf of healthcare providers from patients that have not yet been remitted to providers. These funds payable are not available for our use and liquidity, and are offset on our balance sheet by an aggregated funds payable liability.
Our liquidity is influenced by many factors, including timing of revenue and corresponding cash collections, the amount and timing of investments in strategic initiatives, our investments in property, equipment, and software, as well as other factors described under “Risk factors” in the 2024 Form 10-K. Depending on the severity and direct impact of these factors on us, we may not be able to secure additional financing on acceptable terms, or at all.
Cash Flows
Cash flows from operating, investing, and financing activities for the six months ended June 30, 2025 and June 30, 2024, are summarized in the following table:
Six months ended June 30, 2025Change
($ in thousands)20252024AmountChange
Net cash provided by operating activities$161,009 $26,180 $134,829 515.0 %
Net cash used in investing activities(61,718)(12,428)(49,290)396.6 %
Net cash provided by financing activities7,596 21,278 (13,682)(64.3)%
Net increase in cash and restricted cash$106,887 $35,030 $71,857 205.1 %
Cash Flows Provided by Operating Activities
Cash flows provided by operating activities were $161.0 million for the six months ended June 30, 2025 as compared to $26.2 million for the six months ended June 30, 2024, an increase of $134.8 million. This increase is largely driven by increases in revenue and net income, as well as changes in working capital.
35

Table of Contents
Cash Flows Used in Investing Activities
Cash flows used in investing activities were $61.7 million for the six months ended June 30, 2025 as compared to $12.4 million for the six months ended June 30, 2024 an increase of cash used of $49.3 million. Cash flows used in investing activities increased due to the purchase of short-term investments totaling $50.5 million during the six months ended June 30, 2025.
Cash Flows Provided By Financing Activities
Cash flows provided by financing activities were $7.6 million for the six months ended June 30, 2025 as compared to $21.3 million for the six months ended June 30, 2024, a decrease of $13.7 million. The decrease was driven by proceeds from last year's IPO, net of underwriting discounts and the corresponding paydown on debt, as well as proceeds from the issuance of debt, net of creditor fees, during the six months ended June 30, 2024. These amounts were offset by a decrease in payments made on debt compared to the prior period, as well as an increase in proceeds from the exercise of stock options during the six months ended June 30, 2025.
Indebtedness
Refer to Item 1, Financial Statements, Notes 11 (Accounts Receivable Securitization) and 12 (Debt), for a description of our Credit Facilities.
Critical Accounting Policies and Estimates
The above discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, and expenses, and disclosures of contingent assets and liabilities. Critical accounting policies are those that we consider to be the most important in portraying our financial condition and results of operations and also require the greatest amount of judgments by management. Judgments or uncertainties regarding the application of these policies may result in materially different amounts being reported under different conditions or using different assumptions.
There have been no material changes to our critical accounting policies and estimates from those disclosed in the 2024 Form 10-K.
Recent Accounting Pronouncements
Refer to Item 1, Financial Statements, Note 2 (Summary of Significant Accounting Policies).
JOBS Act Election
We are currently an “emerging growth company,” as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to certain market risks arising from transactions in the normal course of our business. Such risks are principally associated with credit risk and interest rate risk.
Credit Risk
Credit risk involves the possibility that a counterparty will not meet its obligations under a financial instrument or client contract, leading to a financial loss. Concentrations of credit risk with respect to our clients are limited due to our diversified client base.
36

Table of Contents
We routinely assess the financial strength of our clients through a combination of third-party financial reports, credit monitoring, publicly available information, and direct communication with those clients. We establish payment terms with clients to mitigate credit risk and monitor its accounts receivable credit risk exposure. However, while we actively seek to ensure credit risk, there can be no assurance that in the future it will be able to obtain credit risk insurance at commercially attractive terms or at all.
Interest Rate Risk
Our exposure to interest rate risk is related to our First Lien Credit Facility, which bears interest at SOFR plus 2.25% as of June 30, 2025. A hypothetical 100 basis point increase or decrease in the current effective rate would have an impact on our interest expense of approximately $3.1 million for the three months ended June 30, 2025 or $6.2 million for the six months ended June 30, 2025.
In order to limit exposure to risk, we maintain derivative instruments with creditworthy institutions to hedge against changing interest rate fluctuations. We utilize interest rate swap contracts and other non-derivative hedging instruments to manage such risk.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.
Changes in Internal Control Over Financial Reporting
There were no changes to our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the quarter ended June 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
37

Table of Contents
Part II - Other Information
Item 1. Legal Proceedings
The information required with respect to this Part II, Item 1 can be found under Item 1, Financial Statements, Note 20 (Commitments and Contingencies), to the unaudited consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q.
Item 1A. Risk Factors
There have been no material changes to the risk factors disclosed in the 2024 Form 10-K.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchase of Securities
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On February 19, 2025, Eric Lee (Ric) Sinclair III, our Chief Business Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Sinclair’s plan provides for the exercise of up to 450,162 vested stock options and the associated sale of up 450,162 shares of the Company’s common stock. Mr. Sinclair’s trading plan will expire December 31, 2025, or upon the earlier sale of all the shares subject to the plan.
On June 6, 2025, Matthew Hawkins, our Chief Executive Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. Mr. Hawkins’s plan provides for the exercise of up to 300,000 vested stock options and the associated sale of up 300,000 shares of the Company’s common stock. Mr. Hawkins’s trading plan will expire February 19, 2026, or upon the earlier sale of all the shares subject to the plan.
During the six  months ended June 30, 2025, none of the Company’s other directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408 of Regulation S-K.
38

Table of Contents
Item 6. Exhibits
Exhibit
Number
Exhibit DescriptionFiled
Herewith
3.1
Amended and Restated Certificate of Incorporation of Waystar Holding Corp. (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-8 filed on June 10, 2024).
3.2
Certificate of Amendment of Amended and Restated Certificate of Incorporation of Waystar Holding Corp. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 5, 2025).
3.3
Amended and Restated Bylaws of Waystar Holding Corp. (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-8 filed on June 10, 2024).
10.1
Amendment No. 1 to the Stockholders Agreement among Waystar Holding Corp. and the other parties named therein, dated as of April 10, 2025 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on April 30, 2025).
10.2
Form of Performance Stock Unit Agreement under the Waystar Holding Corp. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 12, 2025).
31.1
Certification of Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
31.2
Certification of Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
X
32.1 *
Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
32.2 *
Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
X
101.INSXBRL Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.X
101.SCHInline XBRL Taxonomy Extension Schema Document.X
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.X
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.X
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.X
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.X
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).X
_______________________________________________________________
XFiled Herewith
† Management contract of compensatory plan or arrangement.
39

Table of Contents
*This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.
The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by the Company in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.
40

Table of Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lehi, Utah, on July 30, 2025.
WAYSTAR HOLDING CORP.
By:/s/ Matthew J. Hawkins
Name:Matthew J. Hawkins
Title:Chief Executive Officer
By:/s/ Steven M. Oreskovich
Name:Steven M. Oreskovich
Title:Chief Financial Officer
41

FAQ

How many KNSA shares are being sold under this Form 144?

64,508 common shares are slated for sale.

What is the aggregate market value of the planned Kiniksa insider sale?

The filing lists an aggregate value of $1,928,595.68.

When is the approximate sale date for the KNSA shares?

The filer indicates an approximate sale date of 07/30/2025.

What percentage of KNSA's outstanding shares does this sale represent?

The 64,508 shares equal roughly 0.09% of the 74,107,668 shares outstanding.

Were there any other insider sales reported in the past three months?

No. The Form 144 states "Nothing to Report" for the prior three-month period.

How were the shares acquired prior to the sale?

They were obtained via option exercises under a registered plan on 07/30/2025 for cash.
Waystar Holding Corp.

NASDAQ:WAY

WAY Rankings

WAY Latest News

WAY Latest SEC Filings

WAY Stock Data

6.18B
117.56M
14.47%
91.94%
1.71%
Health Information Services
Services-computer Integrated Systems Design
Link
United States
LEHI